{
    "id": 9538,
    "name": "multiple myeloma",
    "source": "DOID",
    "definition": "A myeloid neoplasm that is located_in the plasma cells in bone marrow. [url:http\\://en.wikipedia.org/wiki/Multiple_myeloma, url:http\\://www.cancer.gov/dictionary?CdrID=411384]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:9538",
    "evidence": [
        {
            "id": 226,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ilorasertib (ABT-348) displayed efficacy in multiple myeloma cell line xenograft models (PMID: 22935731).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 975,
                "therapyName": "ABT-348",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 70,
                    "pubMedId": 22935731,
                    "title": "Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22935731"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1492,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Revlimid (lenalidomide) treatment resulted in IKZF1 degradation and decreased proliferation of multiple myeloma cells in culture (PMID: 24292625).",
            "molecularProfile": {
                "id": 2606,
                "profileName": "IKZF1 wild-type"
            },
            "therapy": {
                "id": 1164,
                "therapyName": "Lenalidomide",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1409,
                    "pubMedId": 24292625,
                    "title": "Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24292625"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1503,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a preclinical study, DTP3, a synthesized D-tripeptide, demonstrated potent and select activity against multiple myeloma in cell assays and xenograft models (PMID: 25314077). DTP3 disrupted the GADD45B/MAP2K7 interaction, reversing the inhibition of the JNK pathway and inducing apoptosis in cells with aberrant NF-kappaB signaling (PMID: 11713530, PMID: 25314077).",
            "molecularProfile": {
                "id": 2615,
                "profileName": "MAP2K7 wild-type"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1428,
                    "pubMedId": 25314077,
                    "title": "Cancer-selective targeting of the NF-\u03baB survival pathway with GADD45\u03b2/MKK7 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25314077"
                },
                {
                    "id": 1429,
                    "pubMedId": 11713530,
                    "title": "Induction of gadd45beta by NF-kappaB downregulates pro-apoptotic JNK signalling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/11713530"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1605,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VS-4718 inhibited proliferation and decreased migration of PTK2B overexpressing multiple myeloma cells in culture, and decreased tumor growth in mouse models of multiple myeloma with PTK2B overexpression (PMID: 25217697).",
            "molecularProfile": {
                "id": 2746,
                "profileName": "PTK2B over exp"
            },
            "therapy": {
                "id": 1933,
                "therapyName": "VS-4718",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1631,
                    "pubMedId": 25217697,
                    "title": "Pyk2 promotes tumor progression in multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25217697"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2148,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, multiple myeloma cells over expressing RAD51 demonstrated enhanced sensitivity when treated with both B02 and Doxorubicin resulting in increased apoptosis (PMID: 25401086).",
            "molecularProfile": {
                "id": 5652,
                "profileName": "RAD51 over exp"
            },
            "therapy": {
                "id": 2623,
                "therapyName": "Aldoxorubicin + B02",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2655,
                    "pubMedId": 25401086,
                    "title": "A Small-Molecule Inhibitor of RAD51 Reduces Homologous Recombination and Sensitizes Multiple Myeloma Cells to Doxorubicin.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25401086"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2377,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Roscovitine (seliciclib), in combination with Alvocidib (flavopiridol) inhibited growth in multiple myeloma cells over expressing CCNE1 (PMID: 22558078).",
            "molecularProfile": {
                "id": 1805,
                "profileName": "CCNE1 over exp"
            },
            "therapy": {
                "id": 2816,
                "therapyName": "Alvocidib + Seliciclib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3008,
                    "pubMedId": 22558078,
                    "title": "Characterization of cyclin E expression in multiple myeloma and its functional role in seliciclib-induced apoptotic cell death.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22558078"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2470,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, B2M over expressing multiple myeloma cells resistant to Velcade (bortezomib) demonstrated increased apoptotic activity when treated with a combination of Velcade (bortezomib) and anti-beta 2 microglobulin monoclonal antibodies (PMID: 25895124).",
            "molecularProfile": {
                "id": 7941,
                "profileName": "B2M over exp"
            },
            "therapy": {
                "id": 688,
                "therapyName": "Bortezomib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3141,
                    "pubMedId": 25895124,
                    "title": "Anti-\u03b2\u2082-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25895124"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2550,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Vofatamab (B-701) demonstrated safety and resulted in stable disease in 42% (6/14) of multiple myeloma patients overexpressing FGFR3 (Blood (ASH Annual Meeting Abstracts) 2012 120: Abstract 4029).",
            "molecularProfile": {
                "id": 8807,
                "profileName": "FGFR3 over exp"
            },
            "therapy": {
                "id": 2934,
                "therapyName": "Vofatamab",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3280,
                    "pubMedId": null,
                    "title": "A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive",
                    "url": "http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/4029"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2570,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZ8010 inhibited Fgfr3 signaling, induced cell-cycle arrest, and decreased proliferation of multiple myeloma cells over expressing FGFR3 Y373C in culture (PMID: 22869148).",
            "molecularProfile": {
                "id": 13015,
                "profileName": "FGFR3 Y373C FGFR3 over exp"
            },
            "therapy": {
                "id": 2955,
                "therapyName": "AZ8010",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3319,
                    "pubMedId": 22869148,
                    "title": "Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22869148"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2572,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KB004 induced apoptosis in primary human multiple myeloma cells expressing EphA3 in culture (53rd ASH Annual Meeting and Exposition, 2010, abstract #2897).",
            "molecularProfile": {
                "id": 27991,
                "profileName": "EPHA3 positive"
            },
            "therapy": {
                "id": 2954,
                "therapyName": "KB004",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3318,
                    "pubMedId": null,
                    "title": "A Recombinant Antibody to EphA3 with Pro-Apoptotic and Enhanced ADCC Activity Against Various Hematologic Malignancies Shows Selective Inhibition of Colony Formation From Long-Term Culture-Initiating Cells (LTC-ICs) In Primary Leukemia Samples",
                    "url": "http://www.bloodjournal.org/content/116/21/2897"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2578,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PD173074 inhibited Fgfr3 signaling, induced cell-cycle arrest, and decreased proliferation of multiple myeloma cells harboring HRAS H117E and over expression of FGFR3 K650E in culture (PMID: 22869148).",
            "molecularProfile": {
                "id": 13017,
                "profileName": "FGFR3 K650E FGFR3 over exp HRAS K117E"
            },
            "therapy": {
                "id": 2948,
                "therapyName": "PD173074",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3319,
                    "pubMedId": 22869148,
                    "title": "Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22869148"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2582,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PD173074 inhibited Fgfr3 signaling and decreased proliferation and survival of multiple myeloma cells over expressing FGFR3 Y373C in culture (PMID: 22869148).",
            "molecularProfile": {
                "id": 13015,
                "profileName": "FGFR3 Y373C FGFR3 over exp"
            },
            "therapy": {
                "id": 2948,
                "therapyName": "PD173074",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3319,
                    "pubMedId": 22869148,
                    "title": "Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22869148"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3011,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CUDC-907 induced caspase activation and apoptosis in a human multiple myeloma cell line harboring KRAS G12A in culture (PMID: 19490892, PMID: 22693356).",
            "molecularProfile": {
                "id": 2381,
                "profileName": "KRAS G12A"
            },
            "therapy": {
                "id": 709,
                "therapyName": "CUDC-907",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1018,
                    "pubMedId": 22693356,
                    "title": "Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22693356"
                },
                {
                    "id": 2128,
                    "pubMedId": 19490892,
                    "title": "Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19490892"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3012,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Farydak (panobinostat) induced caspase activation and apoptosis in a human multiple myeloma cell line harboring KRAS G12A in culture (PMID: 19490892, PMID: 22693356).",
            "molecularProfile": {
                "id": 2381,
                "profileName": "KRAS G12A"
            },
            "therapy": {
                "id": 1080,
                "therapyName": "Panobinostat",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1018,
                    "pubMedId": 22693356,
                    "title": "Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22693356"
                },
                {
                    "id": 2128,
                    "pubMedId": 19490892,
                    "title": "Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19490892"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3274,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, multiple myeloma cells over expressing FGFR3 G384D had reduced sensitivity to PD173074 in culture, compared to cells with ligand-independent activation of FGFR3 (PMID: 22869148).",
            "molecularProfile": {
                "id": 29849,
                "profileName": "FGFR3 G384D FGFR3 over exp"
            },
            "therapy": {
                "id": 2948,
                "therapyName": "PD173074",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3319,
                    "pubMedId": 22869148,
                    "title": "Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22869148"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3276,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, multiple myeloma cells over expressing FGFR3 G384D had reduced sensitivity to AZD4547 in culture, compared to cells with ligand-independent activation of FGFR3 (PMID: 22869148).",
            "molecularProfile": {
                "id": 29849,
                "profileName": "FGFR3 G384D FGFR3 over exp"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3319,
                    "pubMedId": 22869148,
                    "title": "Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22869148"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3277,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, multiple myeloma cells over expressing FGFR3 G384D had reduced sensitivity to AZ8010 in culture, compared to cells with ligand-independent activation of FGFR3 (PMID: 22869148).",
            "molecularProfile": {
                "id": 29849,
                "profileName": "FGFR3 G384D FGFR3 over exp"
            },
            "therapy": {
                "id": 2955,
                "therapyName": "AZ8010",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3319,
                    "pubMedId": 22869148,
                    "title": "Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22869148"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3411,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BAY 1238097 inhibited tumor growth and was well tolerated in acute myeloid leukemia and multiple myeloma models (American Association for Cancer Research; 2015 Apr 18-22; Abstract nr 3524).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2598,
                "therapyName": "BAY 1238097",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2597,
                    "pubMedId": null,
                    "title": "BAY 1238097, a novel BET inhibitor with strong efficacy in hematological tumor models",
                    "url": "http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=b4807182-6a38-470a-b895-86207d0fe55a&cKey=83e86e35-c100-4b31-9794-2db7bdbb4faf&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3608,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In clinical trials that supported FDA approval, treatment with Farydak (panobinostat), in combination with Velcade (Bortezomib) and dexamethasone, extended progression-free survival to 12 months in patients with multiple myeloma (PMID: 26362997).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1604,
                "therapyName": "Bortezomib + Dexamethasone + Panobinostat",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3880,
                    "pubMedId": 26362997,
                    "title": "Panobinostat for the Treatment of Multiple Myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26362997"
                },
                {
                    "id": 15604,
                    "pubMedId": null,
                    "title": "Farydak (panobinostat) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205353"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3900,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Kyprolis (carfilzomib) and Ricolinostat (ACY-1215) promoted apoptosis and reduced tumor volume in a human multiple myeloma cell line xenograft model (PMID: 25709080).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3384,
                "therapyName": "Carfilzomib + Ricolinostat",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4268,
                    "pubMedId": 25709080,
                    "title": "Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25709080"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3905,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ACY-241, in combination with pomalidomide, demonstrated safety and prolonged survival in multiple myeloma cell line xenograft models (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5380).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3399,
                "therapyName": "Citarinostat + Pomalidomide",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4277,
                    "pubMedId": null,
                    "title": "Selective HDAC inhibition by ricolinostat (ACY-1215) or ACY-241 synergizes with IMiD\u00ae immunomodulatory drugs in Multiple Myeloma (MM) and Mantle Cell Lymphoma (MCL) cells",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/5380.short?rss=1"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4729,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, KW-2478 demonstrated safety and preliminary efficacy in patients with multiple myeloma, with 95.2% (20/21) of patients achieving stable disease (PMID: 26695442).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2762,
                "therapyName": "KW-2478",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4680,
                    "pubMedId": 26695442,
                    "title": "Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26695442"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4816,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, multiple myeloma cells treated with BX-912 demonstrated cell cycle arrest and apoptotic activity (PMID: 25269480).",
            "molecularProfile": {
                "id": 19233,
                "profileName": "PDPK1 positive"
            },
            "therapy": {
                "id": 3657,
                "therapyName": "BX-912",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4747,
                    "pubMedId": 25269480,
                    "title": "Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25269480"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4817,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combinational treatment of BX-912 and Velcade (bortezomib) produced an additive effect in multiple myeloma cells in culture, resulting in decreased cell viability (PMID: 25269480).",
            "molecularProfile": {
                "id": 19233,
                "profileName": "PDPK1 positive"
            },
            "therapy": {
                "id": 3658,
                "therapyName": "Bortezomib + BX-912",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4747,
                    "pubMedId": 25269480,
                    "title": "Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25269480"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4818,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combinatorial treatment of BX-912 and Toposaur (etoposide) produced a synergistic effect in multiple myeloma cells in culture, resulting in decreased cell viability (PMID: 25269480).",
            "molecularProfile": {
                "id": 19233,
                "profileName": "PDPK1 positive"
            },
            "therapy": {
                "id": 3659,
                "therapyName": "BX-912 + Etoposide",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4747,
                    "pubMedId": 25269480,
                    "title": "Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25269480"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4819,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combinatorial treatment of BX-912 and BAY11-7085 produced an additive effect in multiple myeloma cells in culture, resulting in decreased cell viability (PMID: 25269480).",
            "molecularProfile": {
                "id": 19233,
                "profileName": "PDPK1 positive"
            },
            "therapy": {
                "id": 3660,
                "therapyName": "BAY11-7085 + BX-912",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4747,
                    "pubMedId": 25269480,
                    "title": "Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25269480"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4878,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Torkinib (PP242) treatment resulted in decreased mTORC2 signaling, growth inhibition and apoptosis in multiple myeloma cell lines and patient-derived multiple myeloma cells in culture, and reduced tumor growth in cell line xenograft animal models (PMID: 20686120).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2240,
                "therapyName": "Torkinib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4766,
                    "pubMedId": 20686120,
                    "title": "Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20686120"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4879,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Torkinib (PP242) worked synergistically with Velcade (Bortezomib) to induce apoptosis in multiple myoloma cell lines in culture (PMID: 20686120).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3671,
                "therapyName": "Bortezomib + Torkinib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4766,
                    "pubMedId": 20686120,
                    "title": "Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20686120"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4903,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, Selumetinib (AZD6244) demonstrated safety and tolerability but had minimal activity with a complete response achieved in 5.6% (2/36) of refractory multiple myeloma patients (PMID: 26446942).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4786,
                    "pubMedId": 26446942,
                    "title": "A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26446942"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4979,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study ON123300 inhibited growth of multiple myeloma cells with over expression of Nuak1 (Ark5) in cell culture and in cell line xenograft models (PMID: 26873845).",
            "molecularProfile": {
                "id": 19845,
                "profileName": "NUAK1 over exp"
            },
            "therapy": {
                "id": 3705,
                "therapyName": "ON123300",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4822,
                    "pubMedId": 26873845,
                    "title": "Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26873845"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5231,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R406 inhibited proliferation and migration and increased apoptosis of SYK-positive primary multiple myeloma cells in culture (PMID: 26251761).",
            "molecularProfile": {
                "id": 20312,
                "profileName": "SYK positive"
            },
            "therapy": {
                "id": 3782,
                "therapyName": "Tamatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4933,
                    "pubMedId": 26251761,
                    "title": "Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26251761"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5232,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Piceatannol inhibited proliferation and migration and increased apoptosis of SYK-positive primary multiple myeloma cells in culture (PMID: 26251761).",
            "molecularProfile": {
                "id": 20312,
                "profileName": "SYK positive"
            },
            "therapy": {
                "id": 3783,
                "therapyName": "Piceatannol",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4933,
                    "pubMedId": 26251761,
                    "title": "Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26251761"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5233,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BAY 61-3606 inhibited proliferation and migration and increased apoptosis of SYK-positive primary multiple myeloma cells in culture (PMID: 26251761).",
            "molecularProfile": {
                "id": 20312,
                "profileName": "SYK positive"
            },
            "therapy": {
                "id": 2665,
                "therapyName": "BAY 61-3606",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4933,
                    "pubMedId": 26251761,
                    "title": "Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26251761"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5449,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LLL2 inhibited Stat3 signaling and cell proliferation in multiple myeloma cell lines in culture, and inhibited tumor growth in xenograft models (PMID: 21520044).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 3592,
                "therapyName": "LLL12",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5062,
                    "pubMedId": 21520044,
                    "title": "A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21520044"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6686,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of human multiple myeloma cells harboring mutant NRAS in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6687,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of human multiple myeloma cells harboring mutant BRAF in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6688,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human multiple myeloma cells harboring mutant KRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6718,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with the combination of Selinexor (KPT-330), Doxil (pegylated liposomal doxorubicin), and Dexamethasone resulted in very good partial response in 20% (2/10), partial response in 20% (2/10), minimal response in 20% (2/10), and stable disease in 30% (3/10) of patients with relapsed or refractory multiple myeloma (J Clin Oncol 34, 2016 (suppl; abstr 8013)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3356,
                "therapyName": "Dexamethasone + Pegylated liposomal-doxorubicin + Selinexor",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5779,
                    "pubMedId": null,
                    "title": "Phase I trial of the combination of selinexor (SEL), liposomal doxorubicin (DOX) and dexamethasone (Dex) for relapsed and refractory multiple myeloma (RRMM).",
                    "url": "http://abstracts.asco.org/176/AbstView_176_168723.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7159,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, INCB054329 and a Jak1 inhibitor synergistically inhibited Myc expression, Stat3 phosphorylation, and cell proliferation of multiple myeloma cell lines in culture, and suppressed tumor growth in xenograft models (Cancer Res 2015;75(15 Suppl):Abstract nr 692).",
            "molecularProfile": {
                "id": 24500,
                "profileName": "MYC pos STAT3 pos"
            },
            "therapy": {
                "id": 2812,
                "therapyName": "INCB054329",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6114,
                    "pubMedId": null,
                    "title": "The BET inhibitor INCB054329 is synergistic with JAK1 inhibition in models of multiple myeloma",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/692.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7613,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, 10058-F4 inhibited growth of multiple myeloma cell lines with MYC amplification and over expression in culture (PMID: 26087190).",
            "molecularProfile": {
                "id": 25920,
                "profileName": "MYC amp MYC over exp"
            },
            "therapy": {
                "id": 3304,
                "therapyName": "10058-F4",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6444,
                    "pubMedId": 26087190,
                    "title": "MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26087190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8011,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, OTS167 treatment of multiple myeloma cells over expressing MELK resulted in apoptosis and prevented cell growth (PMID: 27540718).",
            "molecularProfile": {
                "id": 21948,
                "profileName": "MELK over exp"
            },
            "therapy": {
                "id": 3951,
                "therapyName": "OTS167",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6533,
                    "pubMedId": 27540718,
                    "title": "Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27540718"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8144,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, treatment with Velcade (bortezomib), Revlimid (lenalidomide), and PAT-SM6 resulted in an initial response in a patient with refractory multiple myeloma expressing HSPA5 (GRP78), however, the patient progressed after 8 weeks (PMID: 27029491).",
            "molecularProfile": {
                "id": 26175,
                "profileName": "HSPA5 positive"
            },
            "therapy": {
                "id": 4642,
                "therapyName": "Bortezomib + Lenalidomide + PAT-SM6",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6555,
                    "pubMedId": 27029491,
                    "title": "A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27029491"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8202,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Revlimid (lenalidomide) and PAT-SM6 worked synergistically to inhibit growth of both drug-resistant and sensitive multiple myeloma cell lines with HSPA5 (GRP78) expression in culture (PMID: 27029491).",
            "molecularProfile": {
                "id": 26175,
                "profileName": "HSPA5 positive"
            },
            "therapy": {
                "id": 4658,
                "therapyName": "Lenalidomide + PAT-SM6",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6555,
                    "pubMedId": 27029491,
                    "title": "A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27029491"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8206,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of PAT-SM6 and dexamethasone worked synergistically to inhibit growth of both drug-resistant and sensitive multiple myeloma cell lines with HSPA5 (GRP78) expression in culture (PMID: 27029491).",
            "molecularProfile": {
                "id": 26175,
                "profileName": "HSPA5 positive"
            },
            "therapy": {
                "id": 4659,
                "therapyName": "Dexamethasone + PAT-SM6",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6555,
                    "pubMedId": 27029491,
                    "title": "A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27029491"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8209,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of dexamethasone, Revlimid (lenolidomide), and PAT-SM6 worked synergistically to inhibit growth of a Revlimid (lenolidomide)-resistant multiple myeloma cell lines with HSPA5 (GRP78) expression in culture (PMID: 27029491).",
            "molecularProfile": {
                "id": 26175,
                "profileName": "HSPA5 positive"
            },
            "therapy": {
                "id": 4660,
                "therapyName": "Dexamethasone + Lenalidomide + PAT-SM6",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6555,
                    "pubMedId": 27029491,
                    "title": "A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27029491"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8290,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, multiple myeloma cells were sensitive to GSK1904529A in culture, resulting in decreased cell viability (PMID: 19383820).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2743,
                "therapyName": "GSK1904529A",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2857,
                    "pubMedId": 19383820,
                    "title": "Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19383820"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8436,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Marizomib (NPI-0052) treatment resulted in objective response in 14.8% (4/27) and stable disease in 44.4% (12/27) of patients with relapsed and/or refractory multiple myeloma (PMID: 27117181).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2143,
                "therapyName": "Marizomib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6657,
                    "pubMedId": 27117181,
                    "title": "Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27117181"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8694,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NSC126405 inhibited tumor growth during 11 days of treatment in multiple myeloma cell line xenograft models and 22% (2/9) of the mice demonstrated tumor regression post treatment (PMID: 27530328).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4792,
                "therapyName": "NSC126405",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6710,
                    "pubMedId": 27530328,
                    "title": "Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27530328"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8959,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (POLLUX) that supported FDA approval, the combination of Darzalex (daratumumab), Adexone (dexamethasone), and Revlimid (lenalidomide) resulted in a greater 12 month progression-free survival (83.2% vs 60.1%) and overall response (92.9%; 261/281 vs 76.4%; 211/276) compared to Adexone (dexamethasone) and Revlimid (lenalidomide) alone in patients with relapsed or refractory multiple myeloma (PMID: 27705267; NCT02076009).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4853,
                "therapyName": "Daratumumab + Dexamethasone + Lenalidomide",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6807,
                    "pubMedId": 27705267,
                    "title": "Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27705267"
                },
                {
                    "id": 15498,
                    "pubMedId": null,
                    "title": "Darzalex (Daratumumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761036"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17438,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (MAIA) that supported FDA approval, the combination of Darzalex (daratumumab), Adexone (dexamethasone), and Revlimid (lenalidomide) resulted in an improved rate of progression-free survival at 30 months (70.6% vs 55.6%, HR=0.56, p<0.001) compared control in newly diagnosed multiple myeloma patients ineligible for autologous stem-cell transplantation (PMID: 31141632; NCT02252172).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4853,
                "therapyName": "Daratumumab + Dexamethasone + Lenalidomide",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15498,
                    "pubMedId": null,
                    "title": "Darzalex (Daratumumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761036"
                },
                {
                    "id": 15499,
                    "pubMedId": 31141632,
                    "title": "Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31141632"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9008,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, S63845 potently inhibited survival of MCL1-dependent multiple myeloma cell lines in culture, and induced tumor regression in cell line xenograft models (PMID: 27760111).",
            "molecularProfile": {
                "id": 26203,
                "profileName": "MCL1 positive"
            },
            "therapy": {
                "id": 4858,
                "therapyName": "S63845",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6851,
                    "pubMedId": 27760111,
                    "title": "The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760111"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9111,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, Ricolinostat (ACY-1215) in combination with Revlimid (lenalidomide) and Desamethasone demonstrated safety and preliminary efficacy in relapsed or refractory multiple myeloma patients, resulted in an overall response rate of 55% (21/38) (PMID: 27646843).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4907,
                "therapyName": "Dexamethasone + Lenalidomide + Ricolinostat",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6922,
                    "pubMedId": 27646843,
                    "title": "Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27646843"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9129,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD5153 inhibited proliferation of multiple myeloma cell lines harboring t (11;14) translocation in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 27573426).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4910,
                "therapyName": "AZD5153",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6927,
                    "pubMedId": 27573426,
                    "title": "AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27573426"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9136,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a multiple myeloma cell line harboring FGFR3 Y373C (PMID: 19901323) demonstrated sensitivity to E7090 in culture, resulting in decreased cell viability (PMID: 27535969).",
            "molecularProfile": {
                "id": 3514,
                "profileName": "FGFR3 Y373C"
            },
            "therapy": {
                "id": 4911,
                "therapyName": "E7090",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6928,
                    "pubMedId": 27535969,
                    "title": "E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27535969"
                },
                {
                    "id": 6930,
                    "pubMedId": 19901323,
                    "title": "Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19901323"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9291,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a Velcade (bortezomib)-resistant multiple myeloma cell line demonstrated sensitivity to ONC201 in culture (PMID: 26884599).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1687,
                "therapyName": "ONC201",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7063,
                    "pubMedId": 26884599,
                    "title": "ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26884599"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9449,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Dinaciclib (SCH 727965) decreased cell viability and growth of multiple myeloma cell lines in culture, and decreased tumor growth in multiple myeloma cell line xenograft models (PMID: 26719576).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 719,
                "therapyName": "Dinaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7195,
                    "pubMedId": 26719576,
                    "title": "A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26719576"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9450,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Veliparib (ABT-888) and Dinaciclib (SCH 727965) had a synergistic effect on decreasing survival of multiple myeloma cell lines in culture, and resulted in delayed tumor growth and improved survival of multiple myeloma cell line xenograft models compared to either agent alone (PMID: 26719576).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1277,
                "therapyName": "Dinaciclib + Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7195,
                    "pubMedId": 26719576,
                    "title": "A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26719576"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9451,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of B02 resulted in increased sensitivity to Veliparib (ABT-888), in a multiple myeloma cell line in culture, leading decreased cell viability (PMID: 26719576).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5018,
                "therapyName": "B02 + Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7195,
                    "pubMedId": 26719576,
                    "title": "A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26719576"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9452,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Dinaciclib (SCH 727965) and Adriamycin (doxorubicin) demonstrated synergy in multiple myeloma cell lines in culture, resulting in decreased cell viability (PMID: 26719576).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5019,
                "therapyName": "Dinaciclib + Doxorubicin",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7195,
                    "pubMedId": 26719576,
                    "title": "A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26719576"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9513,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, 42% (20/46) of patients with multiple myeloma demonstrated a partial response, including 3 with a complete response and 2 with a very good partial response, when treated with a combination of Tapalumab and Velcade (bortezomib) (PMID: 27287072).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5062,
                "therapyName": "Bortezomib + Tapalumab",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7246,
                    "pubMedId": 27287072,
                    "title": "Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27287072"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9582,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/IIb trial (GEN501) that supported FDA approval, Darzalex (daratumumab) treatment in patients with heavily pretreated and refractory multiple myeloma resulted in an overall response rate of 36% (15/42) in the 16 mg/kg cohort, with 1 complete response and 3 very good partial responses (PMID: 26308596; NCT00574288).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1630,
                "therapyName": "Daratumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7288,
                    "pubMedId": 26308596,
                    "title": "Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26308596"
                },
                {
                    "id": 15498,
                    "pubMedId": null,
                    "title": "Darzalex (Daratumumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761036"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9584,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (CASTOR) that supported FDA approval, the combination of Darzalex (daratumumab), Velcade (bortezomib), and Adexone (dexamethasone) resulted in a greater 12 month progression-free survival (77.5% vs 29.4%) and overall response (82.9%; 199/240 vs 63.2%; 148/234) compared to Adexone (dexamethasone) and Velcade (bortezomib) alone in relapsed or refractory multiple myeloma patients (PMID: 27557302; NCT02136134).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5100,
                "therapyName": "Bortezomib + Daratumumab + Dexamethasone",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7293,
                    "pubMedId": 27557302,
                    "title": "Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27557302"
                },
                {
                    "id": 15498,
                    "pubMedId": null,
                    "title": "Darzalex (Daratumumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761036"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9835,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, the Phase II recommended dose of Ricolinostat (ACY-1215) combined with Velcade (bortezomib) and Adexone (dexamethasone) resulted in safety and tolerance, and an overall response rate of 37% in patients with multiple myeloma (PMID: 28053023).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5251,
                "therapyName": "Bortezomib + Dexamethasone + Ricolinostat",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7660,
                    "pubMedId": 28053023,
                    "title": "Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28053023"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9837,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, Ricolinostat (ACY-1215) as a single therapy did not result in toxicity nor clinical benefit in multiple myeloma patients (PMID: 28053023).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1613,
                "therapyName": "Ricolinostat",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7660,
                    "pubMedId": 28053023,
                    "title": "Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28053023"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9877,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, bb2121 treatment in multiple myeloma patients resulted in an overall response rate of 78% (7/9), including two patients who experienced complete remission, four patients who achieved partial response, and one patient who experienced stable disease (EORTC-NCI-AACR Symposium, 2016, Abstract #14).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5278,
                "therapyName": "bb2121",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7731,
                    "pubMedId": null,
                    "title": "Clinical remissions and limited toxicity in a first-in-human multicenter study of bb2121, a novel anti-BCMA CAR T cell therapy for relapsed/refractory multiple myeloma",
                    "url": "http://www.ecco-org.eu/Events/ENA2016/Searchable-Programme#anchorScpr"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9883,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, treatment with the combination of Empliciti (elotuzumab) with Revlimid (lenalidomide) and dexamethosone resulted in an overall response rate of 79%, compared to 66% with Revlimid (lenalidomide) and dexamethosone combination therapy in patients with multiple myeloma (PMID: 27493709).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3353,
                "therapyName": "Dexamethasone + Elotuzumab + Lenalidomide",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7736,
                    "pubMedId": 27493709,
                    "title": "Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27493709"
                },
                {
                    "id": 15649,
                    "pubMedId": null,
                    "title": "Empliciti (elotuzumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761035"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9975,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Ficlatuzumab treatment resulted in stable disease in 57% (12/21) of patients with advanced solid tumors and a decrease in phosphorylated Met in one patient with multiple myeloma (PMID: 24901237).",
            "molecularProfile": {
                "id": 1240,
                "profileName": "MET positive"
            },
            "therapy": {
                "id": 740,
                "therapyName": "Ficlatuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7832,
                    "pubMedId": 24901237,
                    "title": "Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24901237"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10055,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with MS417 altered expression of ZCCHC24, HEXIM1, SERPINI1, ZMYND8, and MYC in a multiple myeloma cell line in culture, and these changes correlated with decreased proliferation in culture (PMID: 27903752).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3335,
                "therapyName": "MS417",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7932,
                    "pubMedId": 27903752,
                    "title": "HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27903752"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10056,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Mivebresib (ABBV-075) altered expression of ZCCHC24, HEXIM1, SERPINI1, and MYC in a multiple myeloma cell line in culture and in xenograft models, and these changes correlated with inhibition of proliferation in culture and inhibition of tumor growth in xenograft models (PMID: 27903752).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4028,
                "therapyName": "Mivebresib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7932,
                    "pubMedId": 27903752,
                    "title": "HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27903752"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10406,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD1152 (Barasertib) induced apoptosis of multiple myeloma cells overexpressing Aurkb and inhibited tumor growth in xenograft models (PMID: 18076711).",
            "molecularProfile": {
                "id": 4417,
                "profileName": "AURKB over exp"
            },
            "therapy": {
                "id": 662,
                "therapyName": "Barasertib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2427,
                    "pubMedId": 18076711,
                    "title": "The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18076711"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10415,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Tivantinib (ARQ197) treatment only resulted in stable disease in 36% (4/11) of patients with relapsed or refractory multiple myeloma (PMID: 28337527).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 636,
                "therapyName": "Tivantinib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 8429,
                    "pubMedId": 28337527,
                    "title": "Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28337527"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10846,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KDM5-C70 inhibited cell proliferation of a multiple myeloma cell line in culture (PMID: 27214403).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5660,
                "therapyName": "KDM5-C70",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8868,
                    "pubMedId": 27214403,
                    "title": "Structural analysis of human KDM5B guides histone demethylase inhibitor development.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27214403"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10917,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, multiple myeloma cells harboring Nfkb1 activating mutations did not response to LCL161 treatment in culture (PMID: 27841872).",
            "molecularProfile": {
                "id": 27855,
                "profileName": "NFKB1 act mut"
            },
            "therapy": {
                "id": 3641,
                "therapyName": "LCL161",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8927,
                    "pubMedId": 27841872,
                    "title": "IAP antagonists induce anti-tumor immunity in multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27841872"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10918,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, LCL161 treatment followed by Cytoxan (cyclophosphamide) resulted in complete response in 4% (1/25), partial response in 12% (3/25), and molecular response in 4% (1/25) of multiple myeloma patients (PMID: 27841872).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4019,
                "therapyName": "Cyclophosphamide + LCL161",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8927,
                    "pubMedId": 27841872,
                    "title": "IAP antagonists induce anti-tumor immunity in multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27841872"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11008,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TRC694 treatment inhibited proliferation of multiple myeloma cells harboring MAP3K14 (NIK) translocations in culture, and decreased IKKalpha phosphorylation and downstream gene expression, and reduced tumor growth in a MAP3K14 (NIK)-translocated multiple myeloma cell line xenograft model (AACR 2017 Annual Meeting, Abstract nr 4199).",
            "molecularProfile": {
                "id": 27881,
                "profileName": "MAP3K14 rearrange"
            },
            "therapy": {
                "id": 5772,
                "therapyName": "TRC694",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8981,
                    "pubMedId": null,
                    "title": "Inhibition of NF-kB inducing kinase (NIK) selectively abrogates NIK and TRAF3 mutant multiple myeloma tumor growth",
                    "url": "http://www.abstractsonline.com/pp8/#!/4292/presentation/3906"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11009,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TRC694 inhibited proliferation of multiple myeloma cells harboring TRAF3 mutations in culture, and inhibited tumor growth in TRAF3-mutant xenograft models (AACR 2017 Annual Meeting, Abstract nr 4199).",
            "molecularProfile": {
                "id": 27880,
                "profileName": "TRAF3 mutant"
            },
            "therapy": {
                "id": 5772,
                "therapyName": "TRC694",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8981,
                    "pubMedId": null,
                    "title": "Inhibition of NF-kB inducing kinase (NIK) selectively abrogates NIK and TRAF3 mutant multiple myeloma tumor growth",
                    "url": "http://www.abstractsonline.com/pp8/#!/4292/presentation/3906"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11010,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TRC694 inhibited proliferation of multiple myeloma cells harboring BIRC3 mutations in culture (AACR 2017 Annual Meeting, Abstract nr 4199).",
            "molecularProfile": {
                "id": 27882,
                "profileName": "BIRC3 mutant"
            },
            "therapy": {
                "id": 5772,
                "therapyName": "TRC694",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8981,
                    "pubMedId": null,
                    "title": "Inhibition of NF-kB inducing kinase (NIK) selectively abrogates NIK and TRAF3 mutant multiple myeloma tumor growth",
                    "url": "http://www.abstractsonline.com/pp8/#!/4292/presentation/3906"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11019,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, multiple myeloma cells were sensitive to treatment with KITE-585 (Anti-TNFRSF17 CAR T cells), demonstrating cell death in culture and delayed disease progression in cell line xenograft models (AACR Meeting, 2017, abstract nr 4979).",
            "molecularProfile": {
                "id": 27884,
                "profileName": "TNFRSF17 positive"
            },
            "therapy": {
                "id": 5795,
                "therapyName": "KITE-585",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9007,
                    "pubMedId": null,
                    "title": "Development of KITE-585: a fully human BCMA CAR T-cell therapy for the treatment of multiple myeloma",
                    "url": "http://www.aacr.org/Documents/AACR2017_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11152,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Revlimid (lenalidomide) maintenance treatment after stem cell transplant resulted in improved overall survival and progression free survival in patients with multiple myeloma (J Clin Oncol 35, 2017 (suppl; abstr 8037)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1164,
                "therapyName": "Lenalidomide",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9120,
                    "pubMedId": null,
                    "title": "CALGB/ECOG 100104 (Alliance) study: Lenalidomide vs placebo maintenance after stem cell transplant for patients with multiple myeloma\u2014Overall survival and progression-free survival adjusted for treatment crossover",
                    "url": "http://meetinglibrary.asco.org/record/145449/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11158,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, compared to Thalidomide, Revlimid (lenalidomide), when combined with Cytoxan (cyclophosphamide) and Dexamethasone resulted in better induction response (53% vs 60%), improved progression free survival (32.9 vs 35.9 months), and 3 year overall survival (77.0% vs 82.9%) in multiple myeloma patients (J Clin Oncol 35, 2017 (suppl; abstr 8009)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5888,
                "therapyName": "Cyclophosphamide + Dexamethasone + Lenalidomide",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9123,
                    "pubMedId": null,
                    "title": "Lenalidomide induction and maintenance therapy for transplant eligible myeloma patients: Results of the Myeloma XI study.",
                    "url": "http://meetinglibrary.asco.org/record/152934/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11209,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAS4464 inhibited growth and induced apoptosis in multiple myeloma cell lines in culture, resulted in tumor suppression in cell line xenograft models (Cancer Res 2015;75(15 Suppl):Abstract nr 1730).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5897,
                "therapyName": "TAS4464",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9153,
                    "pubMedId": null,
                    "title": "TAS4464, a novel highly potent NEDD8 activating enzyme inhibitor, demonstrates antitumor activity in multiple myeloma through the inactivation of NF-?B pathways",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/1730"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11214,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, TG02 in combination with Kyprolis (carfilzomib) resulted in an overall response rate of 27% (3/11) and durable stable disease in 27% (3/11) of multiple myeloma patients (Blood 2015 126:3052).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5899,
                "therapyName": "Carfilzomib + TG02",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9155,
                    "pubMedId": null,
                    "title": "TG02, an Oral CDK9-Inhibitor, in Combination with Carfilzomib Demonstrated Objective Responses in Carfilzomib Refractory Multiple Myeloma Patients",
                    "url": "http://www.bloodjournal.org/content/126/23/3052?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11280,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Velcade (bortezomib) and Mivebresib (ABBV-075) resulted in increased tumor growth inhibition in a multiple myeloma cell line xenograft model compared to Velcade (bortezomib) alone (PMID: 28416490).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5925,
                "therapyName": "Bortezomib + Mivebresib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9205,
                    "pubMedId": 28416490,
                    "title": "Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416490"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11281,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Vidaza (azacitidine) and Mivebresib (ABBV-075) resulted in increased tumor growth inhibition in a multiple myeloma cell line xenograft model compared to either agent alone (PMID: 28416490).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5924,
                "therapyName": "Azacitidine + Mivebresib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9205,
                    "pubMedId": 28416490,
                    "title": "Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416490"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11531,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a Velcade (bortezomib) resistant multiple myeloma cell line overcame resistance when treatment was combined with DT204, and in xenograft models the combined treatment resulted in delayed tumor growth and improved survival (PMID: 27677741).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6015,
                "therapyName": "Bortezomib + DT204",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9602,
                    "pubMedId": 27677741,
                    "title": "Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27677741"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11533,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, multiple myeloma cells resistant to Kyprolis (carfilzomib) demonstrated re-sensitization to Kyprolis (carfilzomib) in culture when treatment was combined with DT204, showing a synergistic effect and increased apoptotic activity (PMID: 27677741).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6016,
                "therapyName": "Carfilzomib + DT204",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9602,
                    "pubMedId": 27677741,
                    "title": "Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27677741"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11534,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, multiple myeloma cells resistant to Ninlaro (ixazomib) demonstrated re-sensitization to Ninlaro (ixazomib) in culture when treatment was combined with DT204, showing a synergistic effect and increased apoptotic activity (PMID: 27677741).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6017,
                "therapyName": "DT204 + Ixazomib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9602,
                    "pubMedId": 27677741,
                    "title": "Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27677741"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11615,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with multiple myeloma demonstrated a partial response when treated with a combination of Bendamustine and Veliparib (ABT-888) (PMID: 28314788; NCT01326702).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6076,
                "therapyName": "Bendamustine + Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9669,
                    "pubMedId": 28314788,
                    "title": "The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28314788"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11617,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with SJB3-019A induced cell-cycle arrest and apoptosis and decreased viability of multiple myeloma cell lines in culture (PMID: 28270494).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6078,
                "therapyName": "SJB3-019A",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9668,
                    "pubMedId": 28270494,
                    "title": "Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28270494"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11618,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of SJB3-019A and Velcade (bortezomib) worked synergistically to induce cytotoxicity in multiple myeloma cell lines and primary multiple myeloma cells in culture (PMID: 28270494).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6079,
                "therapyName": "Bortezomib + SJB3-019A",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9668,
                    "pubMedId": 28270494,
                    "title": "Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28270494"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11619,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of SJB3-019A and Ricolinostat (ACY-1215) worked synergistically to induce cytotoxicity in multiple myeloma cell lines and primary multiple myeloma cells in culture (PMID: 28270494).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6082,
                "therapyName": "Ricolinostat + SJB3-019A",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9668,
                    "pubMedId": 28270494,
                    "title": "Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28270494"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11620,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of SJB3-019A and Revlimid (lenalidomide) worked synergistically to induce cytotoxicity in multiple myeloma cell lines and primary multiple myeloma cells in culture (PMID: 28270494).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6080,
                "therapyName": "Lenalidomide + SJB3-019A",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9668,
                    "pubMedId": 28270494,
                    "title": "Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28270494"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11621,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of SJB3-019A and Pomalyst (pomalidomide) worked synergistically to induce cytotoxicity in multiple myeloma cell lines and primary multiple myeloma cells in culture (PMID: 28270494).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6081,
                "therapyName": "Pomalidomide + SJB3-019A",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9668,
                    "pubMedId": 28270494,
                    "title": "Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28270494"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11672,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Velcade (bortezomib) and EDO-S101 induced cell-cycle arrest and apoptosis, and worked synergistically to decrease viability of multiple myeloma cell lines in culture (PMID: 28753594).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6105,
                "therapyName": "Bortezomib + Tinostamustine",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9700,
                    "pubMedId": 28753594,
                    "title": "The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28753594"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11673,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Kyprolis (carfilzomib) and EDO-S101 worked synergistically to decrease viability of multiple myeloma cell lines and primary cells in culture, including a cell line with resistance to Velcade (bortezomib) (PMID: 28753594).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6106,
                "therapyName": "Carfilzomib + Tinostamustine",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9700,
                    "pubMedId": 28753594,
                    "title": "The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28753594"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11674,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with EDO-S101 induced apoptosis and decreased viability of a multiple myeloma cell line in culture (PMID: 28753594).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6104,
                "therapyName": "Tinostamustine",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9700,
                    "pubMedId": 28753594,
                    "title": "The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28753594"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11687,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Delanzomib (CEP-1877) and EDO-S101 worked synergistically to decrease viability of a multiple myeloma cell line in culture (PMID: 28753594).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6109,
                "therapyName": "Delanzomib + Tinostamustine",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9700,
                    "pubMedId": 28753594,
                    "title": "The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28753594"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11868,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with BC2059 decreased proliferation and induced apoptosis of several human multiple myeloma cell lines and primary multiple myeloma cells with activated canonical Wnt signaling in culture, and delayed tumor growth in a multiple myeloma cell line xenograft model (PMID: 28500235).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6190,
                "therapyName": "BC2059",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9885,
                    "pubMedId": 28500235,
                    "title": "\u03b2-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28500235"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11871,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BC2059 and Velcade (bortezomib) worked additively or synergistically in several human multiple myeloma cell lines and primary multiple myeloma cells with activated canonical Wnt signaling in culture (PMID: 28500235).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6191,
                "therapyName": "BC2059 + Bortezomib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9885,
                    "pubMedId": 28500235,
                    "title": "\u03b2-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28500235"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12094,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, P-BCMA-101 CAR-T cells eliminated tumor cells and improved survival in cell line xenograft models of multiple myeloma (Blood 2016 128 (22):2127).",
            "molecularProfile": {
                "id": 27884,
                "profileName": "TNFRSF17 positive"
            },
            "therapy": {
                "id": 6280,
                "therapyName": "P-BCMA-101 CAR-T cells",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10031,
                    "pubMedId": null,
                    "title": "A Novel Bcma-Specific, Centyrin-Based CAR-T Product for the Treatment of Multiple Myeloma",
                    "url": "http://www.bloodjournal.org/content/128/22/2127?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12173,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, Cometriq (Cabometyx, cabozantinib) treatment did not demonstrate significant efficacy, resulting in a minimal response in 9% (1/11), stable disease in 73% (8/11), and progression in 18% (2/11) of patients with relapsed and/or refractory multiple myeloma (PMID: 27020089; NCT01866293).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10130,
                    "pubMedId": 27020089,
                    "title": "Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020089"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12179,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Isatuximab (SAR650984) treatment resulted in complete response in 6% (2/34), partial response in 18% (6/34), and stable disease in 41% (14/34) of patients with relapsed or refractory multiple myeloma (J Clin Oncol 32:5s, 2014 (suppl; abstr 8532)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6331,
                "therapyName": "Isatuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10137,
                    "pubMedId": null,
                    "title": "A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory multiple myeloma.",
                    "url": "http://meetinglibrary.asco.org/record/94588/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12203,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, A-485 treatment inhibited proliferation in multiple myeloma cell lines in culture (PMID: 28953875).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6354,
                "therapyName": "A-485",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10155,
                    "pubMedId": 28953875,
                    "title": "Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28953875"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12213,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GNE-272 treatment resulted in anti-proliferative activity in multiple myeloma cell lines in culture (PMID: 27682507).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6362,
                "therapyName": "GNE-272",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10161,
                    "pubMedId": 27682507,
                    "title": "Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27682507"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12220,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, treatment with Filansenib (ARRY-520) demonstrated safety, and resulted in an overall response rate of 16% (5/31), clinical benefit rate of 23% (7/31), and median overall survival of 19.0 months in the Phase II portion in patients with refractory or relapsed multiple myeloma (PMID: 28817190, NCT00821249).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6365,
                "therapyName": "Filanesib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10176,
                    "pubMedId": 28817190,
                    "title": "A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28817190"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12223,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, treatment with the combination of Filansenib (ARRY-520) and dexamethasone in a Phase II cohort resulted in an overall response rate of 15% (8/54), clinical benefit rate of 20% (11/54), and median overall survival of 10.7 months in patients with refractory or relapsed multiple myeloma (PMID: 28817190, NCT00821249).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6367,
                "therapyName": "Dexamethasone + Filanesib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10176,
                    "pubMedId": 28817190,
                    "title": "A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28817190"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12225,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FT671 treatment blocked proliferation of multiple myeloma cells in culture and inhibited tumor growth in multiple myeloma cell line xenograft models (PMID: 29045389).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6369,
                "therapyName": "FT671",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10182,
                    "pubMedId": 29045389,
                    "title": "Molecular basis of USP7 inhibition by selective small-molecule inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29045389"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12281,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 176 inhibited tumor growth in a multiple myeloma cell line xenograft model (Cancer Res July 1 2017 (77) (13 Supplement) 2027).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6423,
                "therapyName": "AMG 176",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10260,
                    "pubMedId": null,
                    "title": "Abstract 2027: Preclinical evaluation of AMG 176, a novel, potent and selective Mcl-1 inhibitor with robust anti-tumor activity in Mcl-1 dependent cancer models",
                    "url": "cancerres.aacrjournals.org/content/77/13_Supplement/2027"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12297,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with SNS-510 decreased PDPK1 pathway signaling and proliferation of multiple myeloma cell lines in culture (Mol Cancer Ther, Dec 1 2015 (14) (12 Supplement 2) C198).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6432,
                "therapyName": "SNS-510",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10296,
                    "pubMedId": null,
                    "title": "Abstract C198: PDK1 inhibitors SNS-229 and SNS-510 cause pathway modulation, apoptosis and tumor regression in hematologic cancer models in addition to solid tumors",
                    "url": "http://mct.aacrjournals.org/content/14/12_Supplement_2/C198"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12593,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Venclexta (venetoclax) treatment resulted in an overall response rate of 21% (14/66) in patients with relapsed or refractory multiple myeloma, with 86% (12/14) of responses observed in patients harboring t(11; 14), which lead to higher Bcl2 expression level compared to Bcl2l1 and Mcl1 (PMID: 29018077; NCT01794520).",
            "molecularProfile": {
                "id": 1785,
                "profileName": "BCL2 over exp"
            },
            "therapy": {
                "id": 1562,
                "therapyName": "Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10464,
                    "pubMedId": 29018077,
                    "title": "Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29018077"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12596,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, bb2121 treatment resulted in an overall response of 89% (16/18) in multiple myeloma patients (ASH 59th Annual Meeting and Exposition, Dec 2017, Abstract 740; NCT02658929).",
            "molecularProfile": {
                "id": 27884,
                "profileName": "TNFRSF17 positive"
            },
            "therapy": {
                "id": 5278,
                "therapyName": "bb2121",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10469,
                    "pubMedId": null,
                    "title": "Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy",
                    "url": "https://ash.confex.com/ash/2017/webprogram/Paper107984.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12646,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, BI-505 treatment resulted in stable disease in 20% (7/35) of melanoma patients, and saturation of Icam1 molecule on bone marrow myeloma cells in one patient (PMID: 25712687; NCT01025206).",
            "molecularProfile": {
                "id": 23631,
                "profileName": "ICAM1 positive"
            },
            "therapy": {
                "id": 6547,
                "therapyName": "BI-505",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10532,
                    "pubMedId": 25712687,
                    "title": "A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25712687"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12778,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a multiple myeloma cell line with KDM6A loss demonstrated sensitivity to treatment with GSK343, resulting in cell-cycle arrest and increased apoptosis in culture (PMID: 29045832).",
            "molecularProfile": {
                "id": 27321,
                "profileName": "KDM6A loss"
            },
            "therapy": {
                "id": 2701,
                "therapyName": "GSK343",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10712,
                    "pubMedId": 29045832,
                    "title": "UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29045832"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12779,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a multiple myeloma cell line demonstrated sensitivity to treatment with GSK126, resulting in decreased viability in culture and decreased tumor growth in xenograft models (PMID: 29045832).",
            "molecularProfile": {
                "id": 27321,
                "profileName": "KDM6A loss"
            },
            "therapy": {
                "id": 2925,
                "therapyName": "GSK126",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10712,
                    "pubMedId": 29045832,
                    "title": "UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29045832"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14191,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, MV-NIS treatment resulted in enhanced T-cell response to tumor antigens in 40% (4/10) of patients with multiple myeloma (Journal of Clinical Oncology 36, no. 5_suppl (February 10 2018) 218-218; NCT00450814).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6125,
                "therapyName": "MV-NIS",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11501,
                    "pubMedId": null,
                    "title": "T cell responses to tumor associated antigens in multiple myeloma patients treated with MV-NIS, an oncolytic measles virus.",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.5_suppl.218"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14476,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Marizomib (NPI-0052) in combination with Pomalyst (pomalidomide) and low-dose dexamethasone resulted in an overall response rate of 53% (19/36) and a clinical benefit rate of 64% (23/36) in patients with relapsed and refractory multiple myeloma (PMID: 29076150).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7093,
                "therapyName": "Dexamethasone + Marizomib + Pomalidomide",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11645,
                    "pubMedId": 29076150,
                    "title": "A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29076150"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14982,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GEN1029 demonstrated cytotoxicity towards patient-derived multiple myeloma cells, and the cell lysis level correlated with their Tnfrsf10b (Dr5) expression levels (Blood 2017 130(Suppl 1): 1835).",
            "molecularProfile": {
                "id": 23094,
                "profileName": "TNFRSF10B positive"
            },
            "therapy": {
                "id": 7299,
                "therapyName": "GEN1029",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11936,
                    "pubMedId": null,
                    "title": "Potent Ex Vivo Anti-Tumor Activity in Relapsed Refractory Multiple Myeloma Using Novel DR5-Specific Antibodies with Enhanced Capacity to Form Hexamers upon Target Binding",
                    "url": "http://www.bloodjournal.org/content/130/Suppl_1/1835?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15322,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, S63845 treatment of a transformed murine B-ALL cell line with Mcl1 V249L, identified in multiple myeloma patient samples, resulted in cell death (PMID: Blood 2018 132:951).",
            "molecularProfile": {
                "id": 30981,
                "profileName": "MCL1 V249L"
            },
            "therapy": {
                "id": 4858,
                "therapyName": "S63845",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13096,
                    "pubMedId": null,
                    "title": "Myeloma Patient-Derived MCL1 Point Mutations Can Influence MCL1-Inhibitor Function",
                    "url": "http://www.bloodjournal.org/content/132/Suppl_1/951?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15323,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, S63845 treatment of a transformed murine B-ALL cell line with Mcl1 N223S, identified in multiple myeloma patient samples, resulted in cell death (PMID: Blood 2018 132:951).",
            "molecularProfile": {
                "id": 30982,
                "profileName": "MCL1 N223S"
            },
            "therapy": {
                "id": 4858,
                "therapyName": "S63845",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13096,
                    "pubMedId": null,
                    "title": "Myeloma Patient-Derived MCL1 Point Mutations Can Influence MCL1-Inhibitor Function",
                    "url": "http://www.bloodjournal.org/content/132/Suppl_1/951?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15324,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, S63845 treatment of a transformed murine B-ALL cell line with Mcl1 R214Q, identified in multiple myeloma patient samples, resulted in cell death (PMID: Blood 2018 132:951).",
            "molecularProfile": {
                "id": 30983,
                "profileName": "MCL1 R214Q"
            },
            "therapy": {
                "id": 4858,
                "therapyName": "S63845",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13096,
                    "pubMedId": null,
                    "title": "Myeloma Patient-Derived MCL1 Point Mutations Can Influence MCL1-Inhibitor Function",
                    "url": "http://www.bloodjournal.org/content/132/Suppl_1/951?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15325,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, S63845 treatment of a transformed murine B-ALL cell line with Mcl1 L267V, identified in multiple myeloma patient samples, did not result in cell death (PMID: Blood 2018 132:951).",
            "molecularProfile": {
                "id": 30984,
                "profileName": "MCL1 L267V"
            },
            "therapy": {
                "id": 4858,
                "therapyName": "S63845",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13096,
                    "pubMedId": null,
                    "title": "Myeloma Patient-Derived MCL1 Point Mutations Can Influence MCL1-Inhibitor Function",
                    "url": "http://www.bloodjournal.org/content/132/Suppl_1/951?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15326,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD5991 treatment of a transformed murine B-ALL cell line with Mcl1 L267V, identified in multiple myeloma patient samples, did not induce cell apoptosis (PMID: Blood 2018 132:951).",
            "molecularProfile": {
                "id": 30984,
                "profileName": "MCL1 L267V"
            },
            "therapy": {
                "id": 6425,
                "therapyName": "AZD5991",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13096,
                    "pubMedId": null,
                    "title": "Myeloma Patient-Derived MCL1 Point Mutations Can Influence MCL1-Inhibitor Function",
                    "url": "http://www.bloodjournal.org/content/132/Suppl_1/951?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15936,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, treatment with combined Avastin (bevacizumab), Evofosfamide (TH-302) therapy, and Adexone (dexamethasone) was well tolerated in patients with relapsed/refractory multiple myeloma and resulted in a disease control rate of 78.6% (22/28, stable disease or better), 3.6% (1/28) complete and 7.1% (2/28) partial responses, a 25% 6-month progression-free survival rate, a median progression-free survival of 2.2 months, and a median overall survival of 9.0 months (PMID: 30279233; NCT01522872).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7823,
                "therapyName": "Bevacizumab + Dexamethasone + Evofosfamide",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14018,
                    "pubMedId": 30279233,
                    "title": "A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30279233"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15937,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Evofosfamide (TH-302) therapy plus Adexone (dexamethasone) was well tolerated in patients with relapsed/refractory multiple myeloma and resulted in a disease control rate of 83.9% (26/31, stable disease or better), 3.3% (1/31) very good partial responses and 9.7% (3/31) partial responses, a 40% 6-month progression-free survival rate, a median progression-free survival of 4.4 months, and a median overall survival of 12.8 months (PMID: 30279233; NCT01522872).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7824,
                "therapyName": "Dexamethasone + Evofosfamide",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14018,
                    "pubMedId": 30279233,
                    "title": "A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30279233"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15943,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CB-5083 treatment of multiple myeloma cell lines and xenografts resulted in cell death and decreased tumor growth, respectively (PMID: 28878026).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1944,
                "therapyName": "CB-5083",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14057,
                    "pubMedId": 28878026,
                    "title": "The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28878026"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16207,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, GSK2857916 demonstrated manageable safety and preliminary activity in patients with multiple myeloma, with 60% (21/35) of patients in part 2 receiving the recommended phase 2 dose achieving a response (1 stringent complete response (CR), 1 CR, 2 very good partial responses (PR), and 3 PR) (PMID: 30442502; NCT02064387).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7747,
                "therapyName": "GSK2857916",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 13815,
                    "pubMedId": 30442502,
                    "title": "Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30442502"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16596,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, DFRF4539A demonstrated low activity in multiple myeloma patients, with partial responses in 5% (2/39), minimal response in 3% (1/39), stable disease in 46% (18/39), and progressive disease in 41% (16/39) of patients (PMID: 30718503; NCT01432353).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8105,
                "therapyName": "DFRF4539A",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 14637,
                    "pubMedId": 30718503,
                    "title": "Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30718503"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16612,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Lorvotuzumab Mertansine (IMGN901) demonstrated safety and preliminary efficacy, resulted in partial response in 5.7% (2/35), minor response in 11.4% (4/35), and stable disease in 42.9% (15/35) of patients with NCAM1 (CD56)-positive relapsed and relapsed-refractory multiple myeloma, with a median progression-free survival of 26.1 weeks (PMID: 30340993; NCT00346255).",
            "molecularProfile": {
                "id": 31711,
                "profileName": "NCAM1 positive"
            },
            "therapy": {
                "id": 8107,
                "therapyName": "Lorvotuzumab Mertansine",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14638,
                    "pubMedId": 30340993,
                    "title": "A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30340993"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17441,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (ALCYONE) that supported FDA approval, the combination of Darzalex (daratumumab), Velcade (bortezomib), Alkeran (melphalan), and Adasone (prednisone) resulted in improved 18-month progression-free survival rate (71.6% vs 50.2%, HR=0.50, p<0.001) and overall response rate (90.9% vs 73.9%, p<0.001) compared to control in newly diagnosed multiple myeloma patients ineligible for autologous stem-cell transplantation (PMID: 29231133; NCT02195479).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8506,
                "therapyName": "Bortezomib + Daratumumab + Melphalan + Prednisone",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15498,
                    "pubMedId": null,
                    "title": "Darzalex (Daratumumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761036"
                },
                {
                    "id": 15500,
                    "pubMedId": 29231133,
                    "title": "Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29231133"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17442,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial (EQUULEUS) that supported FDA approval, Darzalex (Daratumumab) in combination with Pomalyst (pomalidomide) and Adexone (dexamethasone) resulted in an objective response rate of 60% (61/103) in patients with relapsed or refractory multiple myeloma, with a median progression-free survival of 8.8 months and a median overall survival of 17.5 months (PMID: 28637662; NCT01998971).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7751,
                "therapyName": "Daratumumab + Dexamethasone + Pomalidomide",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15498,
                    "pubMedId": null,
                    "title": "Darzalex (Daratumumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761036"
                },
                {
                    "id": 15501,
                    "pubMedId": 28637662,
                    "title": "Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28637662"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17508,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (STORM) that supported FDA approval, Xpovio (selinexor) in combination with Adexone (dexamethasone) resulted in an overall response rate of 25.3% (21/83, 1 stringent complete response, 4 very good partial response, 16 partial response) in patients with penta-refractory multiple myeloma, with a median duration of response of 3.8 months (Clin Lymphoma Myeloma Leuk, 2018, 18 (Suppl 1): S249-S250; NCT02336815).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2479,
                "therapyName": "Dexamethasone + Selinexor",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15523,
                    "pubMedId": null,
                    "title": "Xpovio (selinexor) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212306"
                },
                {
                    "id": 15524,
                    "pubMedId": null,
                    "title": "Phase 2b Results of the STORM Study: Oral Selinexor plus Low Dose Dexamethasone (Sd) in Patients with Penta-Refractory Myeloma (penta-MM)",
                    "url": "https://www.sciencedirect.com/science/article/pii/S215226501830898X"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17545,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, addition of Velcade (bortezomib) to melphalan and prednisone combination therapy significantly improved time to progression (24.0 vs 16.6 months, HR=0.48, p<0.001) in patients with newly diagnosed multiple myeloma, with improved partial response rate (71% vs 35%) and complete response rate (30% vs 4%), and prolonged overall survival (HR=0.61, p=0.008) (PMID: 18753647; NCT00111319).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 688,
                "therapyName": "Bortezomib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15605,
                    "pubMedId": null,
                    "title": "Velcade (Bortezomib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021602"
                },
                {
                    "id": 15629,
                    "pubMedId": 18753647,
                    "title": "Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18753647"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17550,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, Velcade (bortezomib) treatment resulted in superior response rate (38% vs 18%, p<0.01), improved time to progression (6.22 vs 3.49 months, HR=0.55, p<0.001), and overall survival (HR=0.57, p=0.001) compared to dexamethasone in patients with relapsed multiple myeloma (PMID: 15958804; NCT00048230).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 688,
                "therapyName": "Bortezomib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15605,
                    "pubMedId": null,
                    "title": "Velcade (Bortezomib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021602"
                },
                {
                    "id": 15631,
                    "pubMedId": 15958804,
                    "title": "Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15958804"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18039,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, KRT-232 (AMG 232) demonstrated acceptable safety, and resulted in stable disease in 50% (5/10) of patients with TP53 wild-type multiple myeloma (PMID: 31359240; NCT01723020).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15968,
                    "pubMedId": 31359240,
                    "title": "Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31359240"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18533,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (CASSIOPEIA) that supported FDA approval, Darzalex (daratumumab) in combination with Velcade (bortezomib), thalidomide, and dexamethasone (VTd) resulted in improved stringent complete response at 100 days post autologous stem-cell transplantation compared to VTd (29%, 157/543 vs 20%, 110/542, OR=1.60, p=0.0010) in patients with newly diagnosed multiple myeloma (PMID: 31171419; NCT02541383).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8768,
                "therapyName": "Bortezomib + Daratumumab + Dexamethasone + Thalidomide",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15498,
                    "pubMedId": null,
                    "title": "Darzalex (Daratumumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761036"
                },
                {
                    "id": 16321,
                    "pubMedId": 31171419,
                    "title": "Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31171419"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18568,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, Thalomid (thalidomide) in combination with dexamethasone (n=103) resulted in significantly improved response rate (63% vs 41%, p=0.0017) compared to dexamethasone alone (n=104) in patients with newly diagnosed multiple myeloma (PMID: 16365178).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8769,
                "therapyName": "Dexamethasone + Thalidomide",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 16327,
                    "pubMedId": 16365178,
                    "title": "Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16365178"
                },
                {
                    "id": 17927,
                    "pubMedId": null,
                    "title": "Thalomid (thalidomide) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020785"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18619,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Oprozomib (ONX 0912) treatment resulted in an objective response rate of 41.0%, 28.1%, and 25.0% in the 2/7, 240/300-mg/day; 5/14, 150/180-mg/day; and 5/14, 240-mg/day cohorts of patients with multiple myeloma (n=95) (PMID: 31142508; NCT01416428).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2422,
                "therapyName": "Oprozomib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 16360,
                    "pubMedId": 31142508,
                    "title": "A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenstr\u00f6m Macroglobulinemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31142508"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18744,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TNB-383B increased survival and reduced tumor burden in a cell-line xenograft model of multiple myeloma (Journal of Clinical Oncology 2018 36:15_suppl, 8034-8034).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8824,
                "therapyName": "TNB-383B",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 16403,
                    "pubMedId": null,
                    "title": "Pre-clinical development of TNB-383B, a fully human T-cell engaging bispecific antibody targeting BCMA for the treatment of multiple myeloma.",
                    "url": "https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.8034"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19454,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MOR202 treatment induced cytotoxicity against CD38-positive multiple myeloma cell lines when co-cultured with macrophages in culture (PMID: 29654274).",
            "molecularProfile": {
                "id": 28560,
                "profileName": "CD38 positive"
            },
            "therapy": {
                "id": 9050,
                "therapyName": "MOR202",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17089,
                    "pubMedId": 29654274,
                    "title": "Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29654274"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19455,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MOR202 treatment supplemented with vitamin D resulted in enhanced cytotoxicity against CD38-positive multiple myeloma cell lines co-cultured with Revlimid (lenalidomide)-treated patient-derived monocytes or macrophages in culture (PMID: 29654274).",
            "molecularProfile": {
                "id": 28560,
                "profileName": "CD38 positive"
            },
            "therapy": {
                "id": 9053,
                "therapyName": "Lenalidomide + MOR202 + Vitamin D",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17089,
                    "pubMedId": 29654274,
                    "title": "Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29654274"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19586,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, multiple myeloma cell lines expressing either low or high levels of TNFRSF17 demonstrated sensitivity to MEDI2228 treatment in culture (Blood (2017) 130 (Supplement 1): 3153).",
            "molecularProfile": {
                "id": 27884,
                "profileName": "TNFRSF17 positive"
            },
            "therapy": {
                "id": 9088,
                "therapyName": "MEDI2228",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17190,
                    "pubMedId": null,
                    "title": "Preclinical Evaluation of MEDI2228, a BCMA-Targeting Pyrrolobenzodiazepine-Linked Antibody Drug Conjugate for the Treatment of Multiple Myeloma",
                    "url": "https://ashpublications.org/blood/article/130/Supplement%201/3153/114444"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19988,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Ulocuplumab (BMS-936564) in combination with Revlimid (lenalidomide) and Adexone (dexamethasone) demonstrated safety and preliminary efficacy, resulted in an overall response rate of 55.2% (16/29) and a clinical benefit rate of 72.4% (21/29) in patients with relapsed multiple myeloma (PMID: 31672767).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3555,
                "therapyName": "Dexamethasone + Lenalidomide + Ulocuplumab",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17648,
                    "pubMedId": 31672767,
                    "title": "A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31672767"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19989,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Ulocuplumab (BMS-936564) in combination with Velcade (bortezomib) and Adexone (dexamethasone) demonstrated safety and preliminary efficacy, resulted in an overall response rate of 25.0% (4/16) and a clinical benefit rate of 50% (8/16) in patients with relapsed multiple myeloma (PMID: 31672767).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3556,
                "therapyName": "Bortezomib + Dexamethasone + Ulocuplumab",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17648,
                    "pubMedId": 31672767,
                    "title": "A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31672767"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20115,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a multiple myeloma cell line demonstrated resistance to treatment with Ninlaro (ixazomib) and was subsequently found to harbor PSMB5 A109V in culture (PMID: 30954557).",
            "molecularProfile": {
                "id": 32055,
                "profileName": "PSMB5 A109V"
            },
            "therapy": {
                "id": 1359,
                "therapyName": "Ixazomib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14923,
                    "pubMedId": 30954557,
                    "title": "Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30954557"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20116,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a multiple myeloma cell line demonstrated resistance to treatment with Ninlaro (ixazomib) and was subsequently found to harbor PSMB5 T80A in culture (PMID: 30954557).",
            "molecularProfile": {
                "id": 32056,
                "profileName": "PSMB5 T80A"
            },
            "therapy": {
                "id": 1359,
                "therapyName": "Ixazomib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14923,
                    "pubMedId": 30954557,
                    "title": "Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30954557"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20117,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a multiple myeloma cell line demonstrated resistance to treatment with Velcade (bortezomib) and was subsequently found to harbor PSMB5 T80A in culture (PMID: 30954557).",
            "molecularProfile": {
                "id": 32056,
                "profileName": "PSMB5 T80A"
            },
            "therapy": {
                "id": 688,
                "therapyName": "Bortezomib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14923,
                    "pubMedId": 30954557,
                    "title": "Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30954557"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20118,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a multiple myeloma cell line demonstrated resistance to treatment with Velcade (bortezomib) and was subsequently found to harbor PSMB5 A109V in culture (PMID: 30954557).",
            "molecularProfile": {
                "id": 32055,
                "profileName": "PSMB5 A109V"
            },
            "therapy": {
                "id": 688,
                "therapyName": "Bortezomib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14923,
                    "pubMedId": 30954557,
                    "title": "Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30954557"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20432,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of DT2216 and S63845 demonstrated synergy in a myeloma cell line dependent on MCL-1 and BCL-XL for survival, resulting in decreased cell viability in culture (PMID: 31792461).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 9348,
                "therapyName": "DT2216 + S63845",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17825,
                    "pubMedId": 31792461,
                    "title": "A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31792461"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20693,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (ICARIA-MM) trial that supported FDA approval, addition of Sarclisa (isatuximab-irfc) to Pomalyst (pomalidomide) and dexamethasone significantly improved progression-free survival (11.5 vs 6.5 months, HR=0.596, p=0.001) in patients with relapsed and refractory multiple myeloma (PMID: 31735560; NCT02990338).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6412,
                "therapyName": "Dexamethasone + Isatuximab + Pomalidomide",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17994,
                    "pubMedId": null,
                    "title": "Sarclisa (isatuximab-irfc) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761113"
                },
                {
                    "id": 17995,
                    "pubMedId": 31735560,
                    "title": "Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31735560"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20801,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, INCB054329 treatment reduced MYC expression and proliferation of myeloma cell lines in culture, and inhibited tumor growth in myeloma cell line xenograft models (PMID: 30206163).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2812,
                "therapyName": "INCB054329",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 18046,
                    "pubMedId": 30206163,
                    "title": "The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30206163"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20802,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of INCB054329 and Pemigatinib (INCB054828) decreased MYC expression and FGFR3 signaling and inhibited tumor growth in a t(4;14)-positive myeloma cell line xenograft model, demonstrating increased efficacy over either agent alone (PMID: 30206163).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 9451,
                "therapyName": "INCB054329 + Pemigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 18046,
                    "pubMedId": 30206163,
                    "title": "The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30206163"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20821,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-169 treatment induced cytotoxicity against multiple myeloma cell lines expressing CD38 in culture, and induced regression in a cell line xenograft model and killing of patient cells, including Darzalex (Daratumumab)-resistant cells, in culture (Cancer Res 2019;79(13 Suppl):Abstract nr 2384).",
            "molecularProfile": {
                "id": 28560,
                "profileName": "CD38 positive"
            },
            "therapy": {
                "id": 9488,
                "therapyName": "TAK-169",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18081,
                    "pubMedId": null,
                    "title": "TAK-169, an exceptionally potent CD38 targeted engineered toxin body, as a novel direct cell kill approach for the treatment of multiple myeloma",
                    "url": "https://cancerres.aacrjournals.org/content/79/13_Supplement/2384"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20822,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-169 treatment induced cytotoxicity against multiple myeloma cell lines overexpressing CD38 in culture, and induced regression in a cell line xenograft model (Cancer Res 2019;79(13 Suppl):Abstract nr 2384).",
            "molecularProfile": {
                "id": 35359,
                "profileName": "CD38 over exp"
            },
            "therapy": {
                "id": 9488,
                "therapyName": "TAK-169",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18081,
                    "pubMedId": null,
                    "title": "TAK-169, an exceptionally potent CD38 targeted engineered toxin body, as a novel direct cell kill approach for the treatment of multiple myeloma",
                    "url": "https://cancerres.aacrjournals.org/content/79/13_Supplement/2384"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20934,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, GDA-201 and Empliciti (elotuzumab) combination therapy demonstrated safety and preliminary efficacy, resulted in complete response in 7.7% (1/13) and stable disease in 30.8% (4/13) of patients with refractory multiple myeloma, with a median duration of response of 2.5 months (Blood (2019) 134 (Supplement_1): 777).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 9520,
                "therapyName": "Elotuzumab + GDA-201",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 18191,
                    "pubMedId": null,
                    "title": "Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)",
                    "url": "https://doi.org/10.1182/blood-2019-130476"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 21256,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, multiple myeloma cells harboring BRAF K601N and with decreased expression of CIC via knockdown demonstrated resistance to the combination therapy of Tafinlar (dabrafenib) and Mekinist (trametinib) in culture (PMID: 32043788).",
            "molecularProfile": {
                "id": 36035,
                "profileName": "BRAF K601N CIC dec exp"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 18309,
                    "pubMedId": 32043788,
                    "title": "CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32043788"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00602693",
            "title": "T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 917,
                    "therapyName": "Sirolimus",
                    "synonyms": null
                },
                {
                    "id": 2311,
                    "therapyName": "Allopurinol + Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00720785",
            "title": "Natural Killer Cells and Bortezomib to Treat Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00734877",
            "title": "UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1851,
                    "therapyName": "Cisplatin + Cyclophosphamide + Doxorubicin + Etoposide",
                    "synonyms": null
                },
                {
                    "id": 1852,
                    "therapyName": "Bortezomib + Dexamethasone + Melphalan + Thalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00903968",
            "title": "Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3348,
                    "therapyName": "Bortezomib + Plerixafor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00918333",
            "title": "Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1964,
                    "therapyName": "Everolimus + Panobinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01084252",
            "title": "Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6331,
                    "therapyName": "Isatuximab",
                    "synonyms": null
                },
                {
                    "id": 6357,
                    "therapyName": "Dexamethasone + Isatuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01146834",
            "title": "Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3345,
                    "therapyName": "Bortezomib + Filgrastim",
                    "synonyms": null
                },
                {
                    "id": 5459,
                    "therapyName": "Bortezomib + Cyclophosphamide + Filgrastim",
                    "synonyms": null
                },
                {
                    "id": 5460,
                    "therapyName": "Bortezomib + Cyclophosphamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01163357",
            "title": "Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 917,
                    "therapyName": "Sirolimus",
                    "synonyms": null
                },
                {
                    "id": 2288,
                    "therapyName": "Bortezomib + Fludarabine + Melphalan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01177397",
            "title": "Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 693,
                    "therapyName": "CC-223",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01177683",
            "title": "Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3349,
                    "therapyName": "Bendamustine + Bortezomib + Pegylated liposomal-doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 1632,
                    "therapyName": "Filgrastim",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01208662",
            "title": "Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 (DFCI 10-106)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3342,
                    "therapyName": "Bortezomib + Dexamethasone + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01239368",
            "title": "Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                
            ]
        },
        {
            "nctId": "NCT01241708",
            "title": "Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma ((Mel/MelVel))",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01251575",
            "title": "Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1166,
                    "therapyName": "Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 2270,
                    "therapyName": "Cyclosporine + Mycophenolate mofetil + Sirolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01287546",
            "title": "A Study of LY2875358 in Participants With Advanced Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1179,
                    "therapyName": "Emibetuzumab + Erlotinib",
                    "synonyms": null
                },
                {
                    "id": 1180,
                    "therapyName": "Emibetuzumab + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 803,
                    "therapyName": "Emibetuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01301807",
            "title": "Carfilzomib Plus Panobinostat in Relapsed/Refractory Multiple Myeloma (MM)",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3438,
                    "therapyName": "Carfilzomib + Panobinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01313897",
            "title": "UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma (NK2010-35)",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01323751",
            "title": "Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2470,
                    "therapyName": "Bortezomib + Dexamethasone",
                    "synonyms": null
                },
                {
                    "id": 1613,
                    "therapyName": "Ricolinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01326702",
            "title": "Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 954,
                    "therapyName": "Veliparib",
                    "synonyms": null
                },
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                },
                {
                    "id": 1231,
                    "therapyName": "Bendamustine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01345019",
            "title": "Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1198,
                    "therapyName": "Denosumab",
                    "synonyms": null
                },
                {
                    "id": 2971,
                    "therapyName": "Zoledronic acid",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01353625",
            "title": "Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1000,
                    "therapyName": "CC-115",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01421524",
            "title": "Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2358,
                    "therapyName": "CC-122",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01428492",
            "title": "Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 625,
                    "therapyName": "Afuresertib",
                    "synonyms": null
                },
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                },
                {
                    "id": 1390,
                    "therapyName": "Dexamethasone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01440582",
            "title": "Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3362,
                    "therapyName": "Bortezomib + Dexamethasone + Lenalidomide + Panobinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01453088",
            "title": "Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1207,
                    "therapyName": "Melphalan",
                    "synonyms": null
                },
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01453101",
            "title": "Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2237,
                    "therapyName": "Fludarabine + Melphalan",
                    "synonyms": null
                },
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01456689",
            "title": "A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2685,
                    "therapyName": "Midazolam",
                    "synonyms": null
                },
                {
                    "id": 2402,
                    "therapyName": "LGH447",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01470131",
            "title": "A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma",
            "phase": "Phase III",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 804,
                    "therapyName": "Masitinib",
                    "synonyms": null
                },
                {
                    "id": 2470,
                    "therapyName": "Bortezomib + Dexamethasone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01522872",
            "title": "Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 1317,
                    "therapyName": "Evofosfamide",
                    "synonyms": null
                },
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01524978",
            "title": "A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01526096",
            "title": "Stem Cell Transplantation for Patients With Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5985,
                    "therapyName": "Basiliximab",
                    "synonyms": null
                },
                {
                    "id": 1632,
                    "therapyName": "Filgrastim",
                    "synonyms": null
                },
                {
                    "id": 1756,
                    "therapyName": "Plerixafor",
                    "synonyms": null
                },
                {
                    "id": 1207,
                    "therapyName": "Melphalan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01547806",
            "title": "Collection of Transplant Stem Cells for Plasma Cell Myeloma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1632,
                    "therapyName": "Filgrastim",
                    "synonyms": null
                },
                {
                    "id": 1756,
                    "therapyName": "Plerixafor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01582295",
            "title": "XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 998,
                    "therapyName": "Cabozantinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01587703",
            "title": "A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 784,
                    "therapyName": "GSK525762",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01592370",
            "title": "Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 2583,
                    "therapyName": "IPH2102",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01609816",
            "title": "Dasatinib in Treating Patients With Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Previously Treated With Autologous Stem Cell Transplant",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 717,
                    "therapyName": "Dasatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01668719",
            "title": "S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3343,
                    "therapyName": "Elotuzumab",
                    "synonyms": null
                },
                {
                    "id": 3342,
                    "therapyName": "Bortezomib + Dexamethasone + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01672736",
            "title": "A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1831,
                    "therapyName": "Bortezomib + Dexamethasone + Linsitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01689987",
            "title": "Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2385,
                    "therapyName": "Cyclophosphamide + Dexamethasone + Hydroxychloroquine + Sirolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01695330",
            "title": "Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01711528",
            "title": "Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3437,
                    "therapyName": "Bortezomib + Dexamethasone + Dinaciclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01723020",
            "title": "A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1452,
                    "therapyName": "KRT-232",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01729091",
            "title": "Study of Umbilical Cord Blood-derived Natural Killer Cells in Conjunction With High Dose Chemotherapy and Autologous Stem Cell Transplant for Patients With Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1390,
                    "therapyName": "Dexamethasone",
                    "synonyms": null
                },
                {
                    "id": 3343,
                    "therapyName": "Elotuzumab",
                    "synonyms": null
                },
                {
                    "id": 1632,
                    "therapyName": "Filgrastim",
                    "synonyms": null
                },
                {
                    "id": 1207,
                    "therapyName": "Melphalan",
                    "synonyms": null
                },
                {
                    "id": 1164,
                    "therapyName": "Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01729338",
            "title": "Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3358,
                    "therapyName": "Bortezomib + Cyclophosphamide + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01734928",
            "title": "Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1622,
                    "therapyName": "Pomalidomide",
                    "synonyms": null
                },
                {
                    "id": 2470,
                    "therapyName": "Bortezomib + Dexamethasone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01794507",
            "title": "A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3436,
                    "therapyName": "Bortezomib + Dexamethasone + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01794520",
            "title": "Study Evaluating ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1562,
                    "therapyName": "Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01822509",
            "title": "Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01827137",
            "title": "WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2893,
                    "therapyName": "WT1 vaccine",
                    "synonyms": null
                },
                {
                    "id": 1164,
                    "therapyName": "Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 1873,
                    "therapyName": "Sargramostim",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01829971",
            "title": "A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1035,
                    "therapyName": "MRX34",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01849783",
            "title": "Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1852,
                    "therapyName": "Bortezomib + Dexamethasone + Melphalan + Thalidomide",
                    "synonyms": null
                },
                {
                    "id": 3435,
                    "therapyName": "Aldoxorubicin + Cisplatin + Cyclophosphamide + Dexamethasone + Etoposide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01863550",
            "title": "Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1390,
                    "therapyName": "Dexamethasone",
                    "synonyms": null
                },
                {
                    "id": 1164,
                    "therapyName": "Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 1624,
                    "therapyName": "Carfilzomib",
                    "synonyms": null
                },
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01866293",
            "title": "Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 998,
                    "therapyName": "Cabozantinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01889420",
            "title": "Phase I Trial of Everolimus, Pomalidomide and Dexamethasone Patients With Relapsed/Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2312,
                    "therapyName": "Dexamethasone + Everolimus + Pomalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01919086",
            "title": "Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1164,
                    "therapyName": "Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 2470,
                    "therapyName": "Bortezomib + Dexamethasone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01947140",
            "title": "Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies (PDX+Romi)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8059,
                    "therapyName": "Pralatrexate + Romidepsin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01953692",
            "title": "A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013)",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01954784",
            "title": "Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3434,
                    "therapyName": "Bortezomib + Cyclosporine + Mycophenolate mofetil",
                    "synonyms": null
                },
                {
                    "id": 1164,
                    "therapyName": "Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01955434",
            "title": "SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4019,
                    "therapyName": "Cyclophosphamide + LCL161",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01962792",
            "title": "Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis), in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3282,
                    "therapyName": "Carfilzomib + Ibrutinib",
                    "synonyms": null
                },
                {
                    "id": 1390,
                    "therapyName": "Dexamethasone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01965353",
            "title": "A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3362,
                    "therapyName": "Bortezomib + Dexamethasone + Lenalidomide + Panobinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01989598",
            "title": "Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1298,
                    "therapyName": "Trametinib + Uprosertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01995708",
            "title": "CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 8367,
                    "therapyName": "CT7/MAGE-A3/WT1 mRNA-electroporated LCs",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01997840",
            "title": "ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1614,
                    "therapyName": "Dexamethasone + Pomalidomide + Ricolinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01998971",
            "title": "A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1622,
                    "therapyName": "Pomalidomide",
                    "synonyms": null
                },
                {
                    "id": 2470,
                    "therapyName": "Bortezomib + Dexamethasone",
                    "synonyms": null
                },
                {
                    "id": 1207,
                    "therapyName": "Melphalan",
                    "synonyms": null
                },
                {
                    "id": 1475,
                    "therapyName": "Thalidomide",
                    "synonyms": null
                },
                {
                    "id": 1164,
                    "therapyName": "Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 2188,
                    "therapyName": "Prednisone",
                    "synonyms": null
                },
                {
                    "id": 1630,
                    "therapyName": "Daratumumab",
                    "synonyms": null
                },
                {
                    "id": 1624,
                    "therapyName": "Carfilzomib",
                    "synonyms": null
                },
                {
                    "id": 1275,
                    "therapyName": "Diphenhydramine",
                    "synonyms": null
                },
                {
                    "id": 3323,
                    "therapyName": "Montelukast",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02030483",
            "title": "Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 1390,
                    "therapyName": "Dexamethasone",
                    "synonyms": null
                },
                {
                    "id": 1164,
                    "therapyName": "Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02034110",
            "title": "Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02036502",
            "title": "A Study of Pembrolizumab (MK-3475) in Combination With Lenalidomide and Dexamethasone in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1390,
                    "therapyName": "Dexamethasone",
                    "synonyms": null
                },
                {
                    "id": 3322,
                    "therapyName": "Lenalidomide + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02057640",
            "title": "MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4565,
                    "therapyName": "Dexamethasone + Ixazomib + Panobinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02061761",
            "title": "Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4197,
                    "therapyName": "Nivolumab + Relatlimab",
                    "synonyms": null
                },
                {
                    "id": 4196,
                    "therapyName": "Relatlimab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02077959",
            "title": "Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3357,
                    "therapyName": "Lenalidomide + Pidilizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02086552",
            "title": "Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4445,
                    "therapyName": "Lenalidomide + Sonidegib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02098109",
            "title": "Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1756,
                    "therapyName": "Plerixafor",
                    "synonyms": null
                },
                {
                    "id": 1632,
                    "therapyName": "Filgrastim",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02099539",
            "title": "A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3060,
                    "therapyName": "ALT-803",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02101944",
            "title": "Viral Protein Production After Dexamethasone, Wild-Type Reovirus, and Carfilzomib in Treating Patients With Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2463,
                    "therapyName": "Carfilzomib + Dexamethasone + Reolysin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02104427",
            "title": "PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2853,
                    "therapyName": "TG-0054",
                    "synonyms": null
                },
                {
                    "id": 1632,
                    "therapyName": "Filgrastim",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02110563",
            "title": "Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3122,
                    "therapyName": "DCR-MYC",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02136134",
            "title": "Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1630,
                    "therapyName": "Daratumumab",
                    "synonyms": null
                },
                {
                    "id": 2470,
                    "therapyName": "Bortezomib + Dexamethasone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02140840",
            "title": "A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02144038",
            "title": "Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2419,
                    "therapyName": "Alpelisib + LGH447",
                    "synonyms": null
                },
                {
                    "id": 2402,
                    "therapyName": "LGH447",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02157636",
            "title": "A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2033,
                    "therapyName": "CPI-0610",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02159365",
            "title": "Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3353,
                    "therapyName": "Dexamethasone + Elotuzumab + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02186834",
            "title": "Selinexor (KPT-330) and Pegylated Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3356,
                    "therapyName": "Dexamethasone + Pegylated liposomal-doxorubicin + Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02188368",
            "title": "Pomalidomide for Lenalidomide for Failures",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1625,
                    "therapyName": "Bortezomib + Carfilzomib + Clarithromycin",
                    "synonyms": null
                },
                {
                    "id": 1674,
                    "therapyName": "Pegylated liposomal-doxorubicin + Pomalidomide",
                    "synonyms": null
                },
                {
                    "id": 1622,
                    "therapyName": "Pomalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02189343",
            "title": "Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed-and-Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1614,
                    "therapyName": "Dexamethasone + Pomalidomide + Ricolinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02192775",
            "title": "UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 6125,
                    "therapyName": "MV-NIS",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02195479",
            "title": "A Study of Combination of Daratumumanb and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                },
                {
                    "id": 1630,
                    "therapyName": "Daratumumab",
                    "synonyms": null
                },
                {
                    "id": 1207,
                    "therapyName": "Melphalan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02199665",
            "title": "Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2985,
                    "therapyName": "Carfilzomib + Dexamethasone + Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02204553",
            "title": "Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "No longer available",
            "therapies": [
                {
                    "id": 1604,
                    "therapyName": "Bortezomib + Dexamethasone + Panobinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02211014",
            "title": "An Open-Label, Phase 1b Study of ACP-196 With and Without Dexamethasone in Subjects With Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1605,
                    "therapyName": "Acalabrutinib",
                    "synonyms": null
                },
                {
                    "id": 1390,
                    "therapyName": "Dexamethasone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02220608",
            "title": "Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3345,
                    "therapyName": "Bortezomib + Filgrastim",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02223598",
            "title": "A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies (CLC-102)",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1944,
                    "therapyName": "CB-5083",
                    "synonyms": null
                },
                {
                    "id": 4513,
                    "therapyName": "CB-5083 + Dexamethasone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02235740",
            "title": "A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1624,
                    "therapyName": "Carfilzomib",
                    "synonyms": null
                },
                {
                    "id": 1839,
                    "therapyName": "Afuresertib + Carfilzomib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02252263",
            "title": "A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2055,
                    "therapyName": "Urelumab",
                    "synonyms": null
                },
                {
                    "id": 2583,
                    "therapyName": "IPH2102",
                    "synonyms": null
                },
                {
                    "id": 3343,
                    "therapyName": "Elotuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02254551",
            "title": "Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1954,
                    "therapyName": "Bortezomib + Sonidegib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02283775",
            "title": "SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients (PomdeSAR)",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6412,
                    "therapyName": "Dexamethasone + Isatuximab + Pomalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02289222",
            "title": "Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3344,
                    "therapyName": "Dexamethasone + Pembrolizumab + Pomalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02291848",
            "title": "Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma (TACTAM)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9602,
                    "therapyName": "MultiTAA-specific T cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02308280",
            "title": "Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02328014",
            "title": "ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3265,
                    "therapyName": "ACP-319",
                    "synonyms": null
                },
                {
                    "id": 1605,
                    "therapyName": "Acalabrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02331368",
            "title": "Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1164,
                    "therapyName": "Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 1207,
                    "therapyName": "Melphalan",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02332850",
            "title": "SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 6352,
                    "therapyName": "Carfilzomib + Isatuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02334865",
            "title": "SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9580,
                    "therapyName": "Lenalidomide + Montanide ISA 51 + Sargramostim + SurVaxM",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02336815",
            "title": "Phase 2b Open-Label Single-Arm Selinexor (KPT-330) + Low-Dose Dexamethasone in Patients w/ Multiple Myeloma Quad-refractory to Previous Therapies",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2479,
                    "therapyName": "Dexamethasone + Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02343042",
            "title": "Phase 1b/2 Study of Selinexor (KPT-330) in Combination w/ Backbone Treatments for Resistant/Refractory Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                },
                {
                    "id": 2479,
                    "therapyName": "Dexamethasone + Selinexor",
                    "synonyms": null
                },
                {
                    "id": 1622,
                    "therapyName": "Pomalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02356159",
            "title": "Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2294,
                    "therapyName": "Cytarabine + Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 2373,
                    "therapyName": "Palifermin",
                    "synonyms": null
                },
                {
                    "id": 2188,
                    "therapyName": "Prednisone",
                    "synonyms": null
                },
                {
                    "id": 1632,
                    "therapyName": "Filgrastim",
                    "synonyms": null
                },
                {
                    "id": 2238,
                    "therapyName": "Methotrexate + Sirolimus + Tacrolimus",
                    "synonyms": null
                },
                {
                    "id": 2292,
                    "therapyName": "Doxorubicin + Etoposide + Fludarabine + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 2291,
                    "therapyName": "Cyclophosphamide + Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02367196",
            "title": "A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7268,
                    "therapyName": "CC-90002 + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 7203,
                    "therapyName": "CC-90002",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02368301",
            "title": "Expanded Access Treatment Protocol CA204-143",
            "phase": "Phase I",
            "recruitment": "Approved for marketing",
            "therapies": [
                {
                    "id": 3353,
                    "therapyName": "Dexamethasone + Elotuzumab + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02372240",
            "title": "A Study of VLX1570 and Dexamethasone in Myeloma Patients",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 5099,
                    "therapyName": "Dexamethasone + VLX1570",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02375555",
            "title": "Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3343,
                    "therapyName": "Elotuzumab",
                    "synonyms": null
                },
                {
                    "id": 3342,
                    "therapyName": "Bortezomib + Dexamethasone + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02391480",
            "title": "A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4028,
                    "therapyName": "Mivebresib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02393248",
            "title": "Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4176,
                    "therapyName": "Cisplatin + Gemcitabine + Pemigatinib",
                    "synonyms": null
                },
                {
                    "id": 4174,
                    "therapyName": "Docetaxel + Pemigatinib",
                    "synonyms": null
                },
                {
                    "id": 8250,
                    "therapyName": "INCMGA00012 + Pemigatinib",
                    "synonyms": null
                },
                {
                    "id": 8249,
                    "therapyName": "Pemigatinib + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 4088,
                    "therapyName": "Epacadostat + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02400242",
            "title": "Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3311,
                    "therapyName": "Citarinostat",
                    "synonyms": null
                },
                {
                    "id": 1390,
                    "therapyName": "Dexamethasone",
                    "synonyms": null
                },
                {
                    "id": 1622,
                    "therapyName": "Pomalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02401295",
            "title": "ATRA, Celecoxib, and Itraconazole as Maintenance",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3433,
                    "therapyName": "Celecoxib + Itraconazole + Tretinoin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02426723",
            "title": "Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3081,
                    "therapyName": "CWP232291",
                    "synonyms": null
                },
                {
                    "id": 4036,
                    "therapyName": "Dexamethasone + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02431208",
            "title": "A Study of Atezolizumab (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) Administered With or Without Lenalidomide in Participants With Multiple Myeloma (MM)",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1164,
                    "therapyName": "Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 1201,
                    "therapyName": "Atezolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02440464",
            "title": "Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3321,
                    "therapyName": "Methotrexate + Tacrolimus",
                    "synonyms": null
                },
                {
                    "id": 1359,
                    "therapyName": "Ixazomib",
                    "synonyms": null
                },
                {
                    "id": 2237,
                    "therapyName": "Fludarabine + Melphalan",
                    "synonyms": null
                },
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02441686",
            "title": "Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3342,
                    "therapyName": "Bortezomib + Dexamethasone + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02465060",
            "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1028,
                    "therapyName": "Erdafitinib",
                    "synonyms": null
                },
                {
                    "id": 995,
                    "therapyName": "Copanlisib",
                    "synonyms": null
                },
                {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                {
                    "id": 706,
                    "therapyName": "Crizotinib",
                    "synonyms": null
                },
                {
                    "id": 930,
                    "therapyName": "Sunitinib",
                    "synonyms": null
                },
                {
                    "id": 1282,
                    "therapyName": "Sapanisertib",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 654,
                    "therapyName": "AZD4547",
                    "synonyms": null
                },
                {
                    "id": 717,
                    "therapyName": "Dasatinib",
                    "synonyms": null
                },
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 807,
                    "therapyName": "Binimetinib",
                    "synonyms": null
                },
                {
                    "id": 822,
                    "therapyName": "Adavosertib",
                    "synonyms": null
                },
                {
                    "id": 660,
                    "therapyName": "Osimertinib",
                    "synonyms": null
                },
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 623,
                    "therapyName": "Afatinib",
                    "synonyms": null
                },
                {
                    "id": 655,
                    "therapyName": "Capivasertib",
                    "synonyms": null
                },
                {
                    "id": 958,
                    "therapyName": "Defactinib",
                    "synonyms": null
                },
                {
                    "id": 765,
                    "therapyName": "GSK2636771",
                    "synonyms": null
                },
                {
                    "id": 956,
                    "therapyName": "Vismodegib",
                    "synonyms": null
                },
                {
                    "id": 1402,
                    "therapyName": "Ado-trastuzumab emtansine",
                    "synonyms": null
                },
                {
                    "id": 2650,
                    "therapyName": "Larotrectinib",
                    "synonyms": null
                },
                {
                    "id": 1016,
                    "therapyName": "Taselisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02477878",
            "title": "Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5995,
                    "therapyName": "BPX-601",
                    "synonyms": null
                },
                {
                    "id": 5992,
                    "therapyName": "Rimiducid",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02504359",
            "title": "Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1359,
                    "therapyName": "Ixazomib",
                    "synonyms": null
                },
                {
                    "id": 3359,
                    "therapyName": "Carmustine + Cytarabine + Etoposide + Melphalan",
                    "synonyms": null
                },
                {
                    "id": 3321,
                    "therapyName": "Methotrexate + Tacrolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02514382",
            "title": "Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3432,
                    "therapyName": "Bortezomib + Dexamethasone + Reolysin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02514668",
            "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6331,
                    "therapyName": "Isatuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02519452",
            "title": "A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7886,
                    "therapyName": "Daratumumab + rHuPH20",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02548962",
            "title": "Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 768,
                    "therapyName": "Ibrutinib",
                    "synonyms": null
                },
                {
                    "id": 3792,
                    "therapyName": "Dexamethasone + Pomalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02568943",
            "title": "An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Available",
            "therapies": [
                {
                    "id": 1604,
                    "therapyName": "Bortezomib + Dexamethasone + Panobinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02569320",
            "title": "HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 4299,
                    "therapyName": "AR-42 + Dexamethasone + Pomalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02576496",
            "title": "Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6104,
                    "therapyName": "Tinostamustine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02576977",
            "title": "Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1622,
                    "therapyName": "Pomalidomide",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1390,
                    "therapyName": "Dexamethasone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02579824",
            "title": "DS-3032b for Relapsed and/or Refractory (RR) Myeloma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2079,
                    "therapyName": "DS-3032b",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02579863",
            "title": "Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1390,
                    "therapyName": "Dexamethasone",
                    "synonyms": null
                },
                {
                    "id": 1164,
                    "therapyName": "Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02603887",
            "title": "Pembrolizumab for Smoldering Multiple Myeloma (SMM)",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02605356",
            "title": "Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 2001,
                    "therapyName": "Radium Ra 223 dichloride",
                    "synonyms": null
                },
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                },
                {
                    "id": 1390,
                    "therapyName": "Dexamethasone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02612779",
            "title": "A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone (EPd) in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3355,
                    "therapyName": "Dexamethasone + Elotuzumab + Pomalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02616640",
            "title": "A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1622,
                    "therapyName": "Pomalidomide",
                    "synonyms": null
                },
                {
                    "id": 1390,
                    "therapyName": "Dexamethasone",
                    "synonyms": null
                },
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02628704",
            "title": "Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 2985,
                    "therapyName": "Carfilzomib + Dexamethasone + Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02633059",
            "title": "Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4392,
                    "therapyName": "Dexamethasone + Idasanutlin + Ixazomib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02649790",
            "title": "Study of the Safety, Tolerability and Efficacy of KPT-8602 in Patients With Relapsed/Refractory Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5687,
                    "therapyName": "KPT-8602",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02654132",
            "title": "Trial of Elotuzumab With or Without Pomalidomide and Low-dose Dexamethasone to Treat Refractory and Relapsed and Refractory Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3792,
                    "therapyName": "Dexamethasone + Pomalidomide",
                    "synonyms": null
                },
                {
                    "id": 3343,
                    "therapyName": "Elotuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02654990",
            "title": "Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1604,
                    "therapyName": "Bortezomib + Dexamethasone + Panobinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02655458",
            "title": "Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3430,
                    "therapyName": "Elotuzumab + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02658396",
            "title": "GO-203-2C + Bortezomib For Relapsed Or Refractory MM",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 3427,
                    "therapyName": "Bortezomib + GO-203-2C",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02658929",
            "title": "Study of bb2121 in Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5278,
                    "therapyName": "bb2121",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02666209",
            "title": "Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "No longer available",
            "therapies": [
                {
                    "id": 3556,
                    "therapyName": "Bortezomib + Dexamethasone + Ulocuplumab",
                    "synonyms": null
                },
                {
                    "id": 3555,
                    "therapyName": "Dexamethasone + Lenalidomide + Ulocuplumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02675452",
            "title": "AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6423,
                    "therapyName": "AMG 176",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02681302",
            "title": "Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence (CPIT001)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02684617",
            "title": "Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155) (KEYNOTE-155)",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4225,
                    "therapyName": "Dinaciclib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02685826",
            "title": "A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Subjects With Newly Diagnosed Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1390,
                    "therapyName": "Dexamethasone",
                    "synonyms": null
                },
                {
                    "id": 3934,
                    "therapyName": "Durvalumab + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02693535",
            "title": "TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1657,
                    "therapyName": "Cobimetinib + Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 623,
                    "therapyName": "Afatinib",
                    "synonyms": null
                },
                {
                    "id": 682,
                    "therapyName": "Talazoparib",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 936,
                    "therapyName": "Temsirolimus",
                    "synonyms": null
                },
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 706,
                    "therapyName": "Crizotinib",
                    "synonyms": null
                },
                {
                    "id": 802,
                    "therapyName": "Abemaciclib",
                    "synonyms": null
                },
                {
                    "id": 930,
                    "therapyName": "Sunitinib",
                    "synonyms": null
                },
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02700841",
            "title": "Enhancing Anti-Myeloma Vaccine Response After Autologous Stem Cell Transplantation",
            "phase": "Phase II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 5344,
                    "therapyName": "Melphalan + PVX-410",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02703779",
            "title": "Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                },
                {
                    "id": 3933,
                    "therapyName": "Filgrastim + Plerixafor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02716805",
            "title": "Phase 1 Study to Assess Safety & Tolerability of Tremelimumab & Durvalumab, Administered With High Dose Chemotherapy and Autologous Stem Cell Transplant",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02718833",
            "title": "A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4031,
                    "therapyName": "Bortezomib + Dexamethasone + Elotuzumab + Panobinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02719613",
            "title": "Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4533,
                    "therapyName": "Bortezomib + Dexamethasone + Elotuzumab + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02720510",
            "title": "A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1080,
                    "therapyName": "Panobinostat",
                    "synonyms": null
                },
                {
                    "id": 3342,
                    "therapyName": "Bortezomib + Dexamethasone + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02722668",
            "title": "UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2281,
                    "therapyName": "Cyclophosphamide + Fludarabine + Mycophenolate mofetil",
                    "synonyms": null
                },
                {
                    "id": 917,
                    "therapyName": "Sirolimus",
                    "synonyms": null
                },
                {
                    "id": 1844,
                    "therapyName": "anti-thymocyte globulin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02722941",
            "title": "Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1080,
                    "therapyName": "Panobinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02726581",
            "title": "Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple Myeloma",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3343,
                    "therapyName": "Elotuzumab",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 3792,
                    "therapyName": "Dexamethasone + Pomalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02727803",
            "title": "Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9016,
                    "therapyName": "anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan",
                    "synonyms": null
                },
                {
                    "id": 9015,
                    "therapyName": "anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 9014,
                    "therapyName": "anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02755597",
            "title": "A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy",
            "phase": "Phase III",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 2470,
                    "therapyName": "Bortezomib + Dexamethasone",
                    "synonyms": null
                },
                {
                    "id": 3436,
                    "therapyName": "Bortezomib + Dexamethasone + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02757326",
            "title": "ABC294640 in Refractory / Relapsed Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3301,
                    "therapyName": "ABC294640",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02765854",
            "title": "Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6598,
                    "therapyName": "Dexamethasone + Ixazomib + Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 6597,
                    "therapyName": "Dexamethasone + Ixazomib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02773030",
            "title": "A Study to Determine Dose and Tolerability of CC-220 Monotherapy, in Combination With Dexamethasone, and in Combination With Dexamethasone and Daratumumab or Bortezomib in Subjects With Relapsed and Refractory Multiple Myeloma (MM)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7738,
                    "therapyName": "Iberdomide",
                    "synonyms": null
                },
                {
                    "id": 7739,
                    "therapyName": "Dexamethasone + Iberdomide",
                    "synonyms": null
                },
                {
                    "id": 7740,
                    "therapyName": "Daratumumab + Dexamethasone + Iberdomide",
                    "synonyms": null
                },
                {
                    "id": 7741,
                    "therapyName": "Bortezomib + Dexamethasone + Iberdomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02780609",
            "title": "Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4221,
                    "therapyName": "Dexamethasone + Melphalan + Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02784483",
            "title": "Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1201,
                    "therapyName": "Atezolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02786485",
            "title": "Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 5992,
                    "therapyName": "Rimiducid",
                    "synonyms": null
                },
                {
                    "id": 6053,
                    "therapyName": "BPX-501",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02802163",
            "title": "Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat",
            "phase": "Phase Ib/II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 4367,
                    "therapyName": "Carfilzomib + Dexamethasone + Lenalidomide + Panobinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02807454",
            "title": "A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma (FUSIONMM-003)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4531,
                    "therapyName": "Daratumumab + Dexamethasone + Durvalumab + Pomalidomide",
                    "synonyms": null
                },
                {
                    "id": 4530,
                    "therapyName": "Daratumumab + Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02831686",
            "title": "A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4500,
                    "therapyName": "Dexamethasone + Ixazomib + Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02833610",
            "title": "A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1198,
                    "therapyName": "Denosumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02851056",
            "title": "Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9781,
                    "therapyName": "Ad5-survivin-transduced autologous DC vaccine + Filgrastim + PCV13 vaccine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02863991",
            "title": "Oral ONC201 in Relapsed/Refractory Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1687,
                    "therapyName": "ONC201",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02874742",
            "title": "Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1630,
                    "therapyName": "Daratumumab",
                    "synonyms": null
                },
                {
                    "id": 3342,
                    "therapyName": "Bortezomib + Dexamethasone + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02880228",
            "title": "Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4612,
                    "therapyName": "Dexamethasone + Lenalidomide + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02890758",
            "title": "Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3060,
                    "therapyName": "ALT-803",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02899052",
            "title": "Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5268,
                    "therapyName": "Carfilzomib + Dexamethasone + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02906332",
            "title": "Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1390,
                    "therapyName": "Dexamethasone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02928029",
            "title": "Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 6161,
                    "therapyName": "Bortezomib + Dexamethasone + Radium Ra 223 dichloride",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02931110",
            "title": "Study of IV CBL0137 in Previously Treated Hematological Subjects",
            "phase": "Phase I",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 3940,
                    "therapyName": "CBL0137",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02943473",
            "title": "Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 768,
                    "therapyName": "Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02948283",
            "title": "Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia",
            "phase": "Phase 0",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4919,
                    "therapyName": "Metformin + Ritonavir",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02951819",
            "title": "A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4951,
                    "therapyName": "Bortezomib + Cyclophosphamide + Daratumumab + Dexamethasone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02952573",
            "title": "Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4950,
                    "therapyName": "Dexamethasone + Erdafitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02963493",
            "title": "A Study of Melflufen in Combination With Dexamethasone in Relapsed Refractory Multiple Myeloma Patients (HORIZON)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7883,
                    "therapyName": "Dexamethasone + Melflufen",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02978235",
            "title": "A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 5897,
                    "therapyName": "TAS4464",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02990338",
            "title": "Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients (ICARIA-MM)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6412,
                    "therapyName": "Dexamethasone + Isatuximab + Pomalidomide",
                    "synonyms": null
                },
                {
                    "id": 3792,
                    "therapyName": "Dexamethasone + Pomalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02992483",
            "title": "Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5814,
                    "therapyName": "MIK665",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02998047",
            "title": "A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6593,
                    "therapyName": "Lintuzumab-Ac225",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03000452",
            "title": "A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION-MM-005)",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4530,
                    "therapyName": "Daratumumab + Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03003728",
            "title": "2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8947,
                    "therapyName": "ALT-803 + Elotuzumab + Melphalan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03004287",
            "title": "2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1207,
                    "therapyName": "Melphalan",
                    "synonyms": null
                },
                {
                    "id": 1624,
                    "therapyName": "Carfilzomib",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 1164,
                    "therapyName": "Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 1390,
                    "therapyName": "Dexamethasone",
                    "synonyms": null
                },
                {
                    "id": 1630,
                    "therapyName": "Daratumumab",
                    "synonyms": null
                },
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                },
                {
                    "id": 1136,
                    "therapyName": "Etoposide",
                    "synonyms": null
                },
                {
                    "id": 1009,
                    "therapyName": "Doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 1475,
                    "therapyName": "Thalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03015792",
            "title": "Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant",
            "phase": "Phase Ib/II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 5240,
                    "therapyName": "Dexamethasone + Ibrutinib + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03017820",
            "title": "VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7269,
                    "therapyName": "VSV-hIFNbeta-NIS",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03018405",
            "title": "A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5998,
                    "therapyName": "NKR-2 cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03019666",
            "title": "Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9665,
                    "therapyName": "Allogeneic NAM NK cells",
                    "synonyms": null
                },
                {
                    "id": 2291,
                    "therapyName": "Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03030261",
            "title": "Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1207,
                    "therapyName": "Melphalan",
                    "synonyms": null
                },
                {
                    "id": 3355,
                    "therapyName": "Dexamethasone + Elotuzumab + Pomalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03031730",
            "title": "MDM2 Inhibitor AMG-232, Carfilzomib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6462,
                    "therapyName": "Carfilzomib + Dexamethasone + KRT-232 + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03068351",
            "title": "Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 937,
                    "therapyName": "TEN-010",
                    "synonyms": null
                },
                {
                    "id": 5957,
                    "therapyName": "Daratumumab + TEN-010",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03091257",
            "title": "A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03104270",
            "title": "Combination Study for High Risk Multiple Myeloma Patients",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5555,
                    "therapyName": "Carfilzomib + Dexamethasone + Elotuzumab + Pomalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03106428",
            "title": "A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 5762,
                    "therapyName": "MEDI7247",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03110562",
            "title": "Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5639,
                    "therapyName": "Bortezomib + Dexamethasone + Selinexor",
                    "synonyms": null
                },
                {
                    "id": 2470,
                    "therapyName": "Bortezomib + Dexamethasone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03110822",
            "title": "A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5550,
                    "therapyName": "Lenalidomide + Methylprednisolone + Ruxolitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03111992",
            "title": "Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5311,
                    "therapyName": "LCL161 + Spartalizumab",
                    "synonyms": null
                },
                {
                    "id": 5397,
                    "therapyName": "CJM112 + Spartalizumab",
                    "synonyms": null
                },
                {
                    "id": 2659,
                    "therapyName": "Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03143985",
            "title": "TEW-7197 in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5875,
                    "therapyName": "Pomalidomide + TEW 7197",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03145181",
            "title": "Dose Escalation Study of JNJ-64007957, a Humanized BCMA CD3 DuoBody\u00ae Antibody, in Participants With Relapsed or Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5708,
                    "therapyName": "JNJ-64007957",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03151811",
            "title": "A Study of Melflufen-dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide (OCEAN)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3792,
                    "therapyName": "Dexamethasone + Pomalidomide",
                    "synonyms": null
                },
                {
                    "id": 7883,
                    "therapyName": "Dexamethasone + Melflufen",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03168100",
            "title": "2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 3342,
                    "therapyName": "Bortezomib + Dexamethasone + Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 3353,
                    "therapyName": "Dexamethasone + Elotuzumab + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03168438",
            "title": "NY-ESO-1-c259T Alone and in Combination With Pembrolizumab for Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5877,
                    "therapyName": "NY-ESO-1-c259T",
                    "synonyms": null
                },
                {
                    "id": 5878,
                    "therapyName": "NY-ESO-1-c259T + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03194867",
            "title": "Isatuximab in Combination With REGN2810 in Relapsed/Refractory Multiple Myeloma (RRMM) Patients",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6335,
                    "therapyName": "Cemiplimab + Isatuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03201250",
            "title": "Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6330,
                    "therapyName": "Cabozantinib + Carfilzomib + Dexamethasone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03215030",
            "title": "A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory Multiple Myeloma (MM)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9180,
                    "therapyName": "Dexamethasone + TAK-573",
                    "synonyms": null
                },
                {
                    "id": 9149,
                    "therapyName": "TAK-573",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03218683",
            "title": "Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies.",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6425,
                    "therapyName": "AZD5991",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03221634",
            "title": "Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 6115,
                    "therapyName": "Daratumumab + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03227432",
            "title": "An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 6118,
                    "therapyName": "Dexamethasone + Elotuzumab + Nivolumab + Pomalidomide",
                    "synonyms": null
                },
                {
                    "id": 6117,
                    "therapyName": "Elotuzumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03246529",
            "title": "A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for thE MobilizatioN of HematopoiEtic Stem Cells for Autologous TransplantatIon in SubjectS With MM (GENESIS)",
            "phase": "Phase III",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 1632,
                    "therapyName": "Filgrastim",
                    "synonyms": null
                },
                {
                    "id": 6832,
                    "therapyName": "BKT140 + Filgrastim",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03256045",
            "title": "Panobinostat, Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6289,
                    "therapyName": "Carfilzomib + Dexamethasone + Panobinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03266692",
            "title": "Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 7383,
                    "therapyName": "ACTR087 + SEA-BCMA",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03267888",
            "title": "Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03269136",
            "title": "Phase 1 Study Of PF-06863135, A BCMA- CD3 Bispecific Ab, In Relapse/ Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9750,
                    "therapyName": "PF-06863135",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03275285",
            "title": "Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients (IKEMA)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7885,
                    "therapyName": "Carfilzomib + Dexamethasone + Isatuximab",
                    "synonyms": null
                },
                {
                    "id": 7884,
                    "therapyName": "Carfilzomib + Dexamethasone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03288480",
            "title": "A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2920,
                    "therapyName": "PT-112",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03288493",
            "title": "P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6280,
                    "therapyName": "P-BCMA-101 CAR-T cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03297606",
            "title": "Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 690,
                    "therapyName": "Bosutinib",
                    "synonyms": null
                },
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 956,
                    "therapyName": "Vismodegib",
                    "synonyms": null
                },
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1657,
                    "therapyName": "Cobimetinib + Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 936,
                    "therapyName": "Temsirolimus",
                    "synonyms": null
                },
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                },
                {
                    "id": 4,
                    "therapyName": "Erlotinib",
                    "synonyms": null
                },
                {
                    "id": 706,
                    "therapyName": "Crizotinib",
                    "synonyms": null
                },
                {
                    "id": 930,
                    "therapyName": "Sunitinib",
                    "synonyms": null
                },
                {
                    "id": 623,
                    "therapyName": "Afatinib",
                    "synonyms": null
                },
                {
                    "id": 717,
                    "therapyName": "Dasatinib",
                    "synonyms": null
                },
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 649,
                    "therapyName": "Axitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03309111",
            "title": "Study of GBR 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8845,
                    "therapyName": "GBR1342",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03314181",
            "title": "A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6347,
                    "therapyName": "Bortezomib + Daratumumab + Dexamethasone + Venetoclax",
                    "synonyms": null
                },
                {
                    "id": 6346,
                    "therapyName": "Daratumumab + Dexamethasone",
                    "synonyms": null
                },
                {
                    "id": 6345,
                    "therapyName": "Daratumumab + Dexamethasone + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03315026",
            "title": "Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3485,
                    "therapyName": "siltuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03319667",
            "title": "Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant (IMROZ)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3342,
                    "therapyName": "Bortezomib + Dexamethasone + Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 7888,
                    "therapyName": "Dexamethasone + Isatuximab + Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 7887,
                    "therapyName": "Bortezomib + Dexamethasone + Isatuximab + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03333746",
            "title": "Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 5239,
                    "therapyName": "Lenalidomide + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03338972",
            "title": "Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 2291,
                    "therapyName": "Cyclophosphamide + Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 7918,
                    "therapyName": "Anti-BCMA CAR T Cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03357952",
            "title": "A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6833,
                    "therapyName": "Daratumumab + JNJ-63723283",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03361306",
            "title": "LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple M",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5033,
                    "therapyName": "Carfilzomib + Dexamethasone + Elotuzumab + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03361748",
            "title": "Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa) (bb2121)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5278,
                    "therapyName": "bb2121",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03374085",
            "title": "A Safety, PK and Efficacy Study of CC-92480 in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9753,
                    "therapyName": "CC-92480 + Dexamethasone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03399799",
            "title": "Dose Escalation Study of JNJ-64407564 in Participants With Relapsed or Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8778,
                    "therapyName": "JNJ-64407564",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03411031",
            "title": "Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3430,
                    "therapyName": "Elotuzumab + Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 1390,
                    "therapyName": "Dexamethasone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03412565",
            "title": "A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6836,
                    "therapyName": "Bortezomib + Daratumumab + Dexamethasone + Melphalan + Prednisone",
                    "synonyms": null
                },
                {
                    "id": 4853,
                    "therapyName": "Daratumumab + Dexamethasone + Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 6835,
                    "therapyName": "Bortezomib + Daratumumab + Dexamethasone + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03424603",
            "title": "Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7413,
                    "therapyName": "STRO-001",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03428373",
            "title": "ASA vs. Rivaroxaban in Newly Diagnosed or Relapsed and Refractory Multiple Myeloma Patients Treated With Len-Dex Combination Therapy. (RithMM)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8718,
                    "therapyName": "Dexamethasone + Lenalidomide + Rivaroxaban",
                    "synonyms": null
                },
                {
                    "id": 8719,
                    "therapyName": "Aspirin + Dexamethasone + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03439280",
            "title": "A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8770,
                    "therapyName": "Dexamethasone + Pomalidomide + TAK-079",
                    "synonyms": null
                },
                {
                    "id": 8739,
                    "therapyName": "TAK-079",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03441958",
            "title": "ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9468,
                    "therapyName": "Cyclophosphamide + ECT-001 cord blood cells + Fludarabine + Mycophenolate mofetil + Tacrolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03481556",
            "title": "Study of Melflufen + Dex With Bortezomib or Daratumumab in Patients With RRMM (ANCHOR)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7743,
                    "therapyName": "Bortezomib + Dexamethasone + Melflufen",
                    "synonyms": null
                },
                {
                    "id": 7744,
                    "therapyName": "Daratumumab + Dexamethasone + Melflufen",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03489525",
            "title": "MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9088,
                    "therapyName": "MEDI2228",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03492138",
            "title": "Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7745,
                    "therapyName": "Dexamethasone + Ixazomib + ONC201",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03502577",
            "title": "BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 7919,
                    "therapyName": "Anti-BCMA CAR T Cells + Cyclophosphamide + Fludarabine + LY3039478",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03506360",
            "title": "Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Participants With Relapsed Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 8831,
                    "therapyName": "Dexamethasone + Ixazomib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03506802",
            "title": "TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 3933,
                    "therapyName": "Filgrastim + Plerixafor",
                    "synonyms": null
                },
                {
                    "id": 1164,
                    "therapyName": "Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 7836,
                    "therapyName": "Aldesleukin + LV-NY-ESO TCR/sr39TK PBSC + RV-NY-ESO TCR PBMC",
                    "synonyms": null
                },
                {
                    "id": 1207,
                    "therapyName": "Melphalan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03525678",
            "title": "A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Subjects With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7747,
                    "therapyName": "GSK2857916",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03530683",
            "title": "A Trial of TTI-622 in Patients With Advanced Relapsed or Refractory Lymphoma or Myeloma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7158,
                    "therapyName": "TTI-622",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03537482",
            "title": "APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8825,
                    "therapyName": "APG-2575",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03539744",
            "title": "A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (CANOVA)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3792,
                    "therapyName": "Dexamethasone + Pomalidomide",
                    "synonyms": null
                },
                {
                    "id": 7746,
                    "therapyName": "Dexamethasone + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03544281",
            "title": "To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7749,
                    "therapyName": "Bortezomib + Dexamethasone + GSK2857916",
                    "synonyms": null
                },
                {
                    "id": 7748,
                    "therapyName": "Dexamethasone + GSK2857916 + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03548207",
            "title": "A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7045,
                    "therapyName": "JNJ-68284528",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03567616",
            "title": "A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 7750,
                    "therapyName": "Dexamethasone + Pomalidomide + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03582033",
            "title": "A Safety Study of SEA-BCMA in Patients With Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7382,
                    "therapyName": "SEA-BCMA",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03591614",
            "title": "Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9685,
                    "therapyName": "DKK1 dendritic cell vaccine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03601078",
            "title": "An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year of Initial Treatment (KarMMa-2)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5278,
                    "therapyName": "bb2121",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03602612",
            "title": "T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7934,
                    "therapyName": "Anti-BCMA CAR T Cells + Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03605719",
            "title": "Dexamethasone, Carfilzomib, & Nivolumab With Reovirus for Relapsed/Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7891,
                    "therapyName": "Carfilzomib + Dexamethasone + Nivolumab + Reolysin",
                    "synonyms": null
                },
                {
                    "id": 7890,
                    "therapyName": "Carfilzomib + Dexamethasone + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03607643",
            "title": "A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 2183,
                    "therapyName": "Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin",
                    "synonyms": "Bevacizumab + FOLFIRINOX"
                },
                {
                    "id": 7247,
                    "therapyName": "Bevacizumab + Cannabidiol + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin",
                    "synonyms": "Bevacizumab + Cannabidiol + FOLFIRINOX"
                },
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                },
                {
                    "id": 7248,
                    "therapyName": "Bortezomib + Cannabidiol",
                    "synonyms": null
                },
                {
                    "id": 7249,
                    "therapyName": "Cannabidiol + Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 7250,
                    "therapyName": "Cannabidiol + Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03634800",
            "title": "Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M) (RISE-M)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03651128",
            "title": "Efficacy and Safety Study of bb2121 Versus Standard Triplet Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5100,
                    "therapyName": "Bortezomib + Daratumumab + Dexamethasone",
                    "synonyms": null
                },
                {
                    "id": 5278,
                    "therapyName": "bb2121",
                    "synonyms": null
                },
                {
                    "id": 6598,
                    "therapyName": "Dexamethasone + Ixazomib + Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 7751,
                    "therapyName": "Daratumumab + Dexamethasone + Pomalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03652064",
            "title": "A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3342,
                    "therapyName": "Bortezomib + Dexamethasone + Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 6835,
                    "therapyName": "Bortezomib + Daratumumab + Dexamethasone + Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 4036,
                    "therapyName": "Dexamethasone + Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 4853,
                    "therapyName": "Daratumumab + Dexamethasone + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03657420",
            "title": "Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 7756,
                    "therapyName": "Dexamethasone + Nab-Rapamycin + Pomalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03672318",
            "title": "Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9782,
                    "therapyName": "ATLCAR.CD138 + Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03687125",
            "title": "Tinostamustine Conditioning and Autologous Stem Cell (TITANIUM1)",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 6104,
                    "therapyName": "Tinostamustine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03701321",
            "title": "Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 5100,
                    "therapyName": "Bortezomib + Daratumumab + Dexamethasone",
                    "synonyms": null
                },
                {
                    "id": 6347,
                    "therapyName": "Bortezomib + Daratumumab + Dexamethasone + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03702725",
            "title": "Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5240,
                    "therapyName": "Dexamethasone + Ibrutinib + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03710421",
            "title": "CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9595,
                    "therapyName": "CS1-CAR T cells + Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03713294",
            "title": "Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3355,
                    "therapyName": "Dexamethasone + Elotuzumab + Pomalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03715478",
            "title": "Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8632,
                    "therapyName": "Dexamethasone + GSK2857916 + Pomalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03729804",
            "title": "Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) ((COBRA))",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3342,
                    "therapyName": "Bortezomib + Dexamethasone + Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 7757,
                    "therapyName": "Carfilzomib + Dexamethasone + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03732703",
            "title": "Myeloma-Developing Regimens Using Genomics (MyDRUG) (MyDRUG)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8165,
                    "therapyName": "Dexamethasone + Enasidenib + Ixazomib + Pomalidomide",
                    "synonyms": null
                },
                {
                    "id": 8166,
                    "therapyName": "Cobimetinib + Dexamethasone + Ixazomib + Pomalidomide",
                    "synonyms": null
                },
                {
                    "id": 8167,
                    "therapyName": "Dexamethasone + Erdafitinib + Ixazomib + Pomalidomide",
                    "synonyms": null
                },
                {
                    "id": 8168,
                    "therapyName": "Dexamethasone + Ixazomib + Pomalidomide + Venetoclax",
                    "synonyms": null
                },
                {
                    "id": 8164,
                    "therapyName": "Abemaciclib + Dexamethasone + Ixazomib + Pomalidomide",
                    "synonyms": null
                },
                {
                    "id": 8169,
                    "therapyName": "Daratumumab + Dexamethasone + Ixazomib + Pomalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03741127",
            "title": "Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101",
            "phase": "Phase I",
            "recruitment": "Enrolling by invitation",
            "therapies": [
                {
                    "id": 5992,
                    "therapyName": "Rimiducid",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03761108",
            "title": "First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9740,
                    "therapyName": "REGN5458",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03763162",
            "title": "Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5100,
                    "therapyName": "Bortezomib + Daratumumab + Dexamethasone",
                    "synonyms": null
                },
                {
                    "id": 6282,
                    "therapyName": "Daratumumab + Dexamethasone + Ixazomib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03770260",
            "title": "Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8633,
                    "therapyName": "Ixazomib + MLN4924",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03773107",
            "title": "LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7758,
                    "therapyName": "Carfilzomib + Dexamethasone + Ruxolitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03782064",
            "title": "Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7774,
                    "therapyName": "DC/myeloma fusion vaccine + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03785184",
            "title": "A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 7759,
                    "therapyName": "Dexamethasone + Lenalidomide + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03829020",
            "title": "Metformin and Nelfinavir in Treating Patients With Relapsed and/or Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7898,
                    "therapyName": "Metformin + Nelfinavir",
                    "synonyms": null
                },
                {
                    "id": 7899,
                    "therapyName": "Bortezomib + Metformin + Nelfinavir",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03837509",
            "title": "INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8376,
                    "therapyName": "Daratumumab + INCB001158",
                    "synonyms": null
                },
                {
                    "id": 1630,
                    "therapyName": "Daratumumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03848845",
            "title": "Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 4)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7912,
                    "therapyName": "GSK2857916 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03910439",
            "title": "Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3144,
                    "therapyName": "Avelumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03933735",
            "title": "A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8824,
                    "therapyName": "TNB-383B",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03942224",
            "title": "Daratumumab, Ixazomib, & Dexamethasone With or Without Bortezomib in Patients With Newly Diagnosed Multiple Myeloma (DeRIVE)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6282,
                    "therapyName": "Daratumumab + Dexamethasone + Ixazomib",
                    "synonyms": null
                },
                {
                    "id": 5100,
                    "therapyName": "Bortezomib + Daratumumab + Dexamethasone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03958656",
            "title": "T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8417,
                    "therapyName": "Anti-SLAMF7 CAR T cells + Cyclophosphamide + Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 5992,
                    "therapyName": "Rimiducid",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03984097",
            "title": "A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8740,
                    "therapyName": "Dexamethasone + Lenalidomide + TAK-079",
                    "synonyms": null
                },
                {
                    "id": 8741,
                    "therapyName": "Bortezomib + Dexamethasone + Lenalidomide + TAK-079",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03997968",
            "title": "A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8486,
                    "therapyName": "CYT01B",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04017130",
            "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of TAK-169 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9488,
                    "therapyName": "TAK-169",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04045028",
            "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4268,
                    "therapyName": "MTIG7192A",
                    "synonyms": null
                },
                {
                    "id": 9143,
                    "therapyName": "Daratumumab + MTIG7192A",
                    "synonyms": null
                },
                {
                    "id": 9144,
                    "therapyName": "MTIG7192A + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04045795",
            "title": "Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6412,
                    "therapyName": "Dexamethasone + Isatuximab + Pomalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04052880",
            "title": "Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8676,
                    "therapyName": "Daratumumab + Ixazomib",
                    "synonyms": null
                },
                {
                    "id": 6835,
                    "therapyName": "Bortezomib + Daratumumab + Dexamethasone + Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 8675,
                    "therapyName": "Daratumumab + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04071457",
            "title": "S1803, Daratumumab/rHuPh20 +/- Lenalidomide as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8708,
                    "therapyName": "Daratumumab + Lenalidomide + rHuPH20",
                    "synonyms": null
                },
                {
                    "id": 1164,
                    "therapyName": "Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04083534",
            "title": "First In Human (FIH) Study of REGN5459 in Patients With Relapsed or Refractory Multiple Myeloma (MM)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9649,
                    "therapyName": "REGN5459",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04083898",
            "title": "Isatuximab, Bendamustine, and Prednisone in Penta-Refractory Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 8721,
                    "therapyName": "Bendamustine + Isatuximab + Prednisone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04091126",
            "title": "Bortezomib, Lenalidomide and Dexamethasone (VRd) With Belantamab Mafodotin Versus VRd Alone in Transplant Ineligible Multiple Myeloma",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3342,
                    "therapyName": "Bortezomib + Dexamethasone + Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 9509,
                    "therapyName": "Bortezomib + Dexamethasone + GSK2857916 + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04108195",
            "title": "A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8777,
                    "therapyName": "Daratumumab + JNJ-64007957",
                    "synonyms": null
                },
                {
                    "id": 8779,
                    "therapyName": "Daratumumab + JNJ-64407564",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04111107",
            "title": "Precision Medicine for Patients With Identified Actionable Mutations",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                
            ]
        },
        {
            "nctId": "NCT04119336",
            "title": "Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8832,
                    "therapyName": "Cyclophosphamide + Dexamethasone + Ixazomib + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04126200",
            "title": "Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8885,
                    "therapyName": "GSK2857916 + GSK3359609",
                    "synonyms": null
                },
                {
                    "id": 7747,
                    "therapyName": "GSK2857916",
                    "synonyms": null
                },
                {
                    "id": 8884,
                    "therapyName": "GSK2857916 + GSK3174998",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04133636",
            "title": "A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma (CARTITUDE-2)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7045,
                    "therapyName": "JNJ-68284528",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04136756",
            "title": "NKTR-255 in Relapsed/Refractory Multiple Myeloma and Non Hodgkin Lymphoma and Combined With Daratumumab for Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9162,
                    "therapyName": "NKTR-255",
                    "synonyms": null
                },
                {
                    "id": 9163,
                    "therapyName": "Daratumumab + NKTR-255",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04140162",
            "title": "Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma With Upfront Daratumumab-based Therapy",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 1164,
                    "therapyName": "Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 6835,
                    "therapyName": "Bortezomib + Daratumumab + Dexamethasone + Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 4853,
                    "therapyName": "Daratumumab + Dexamethasone + Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 8675,
                    "therapyName": "Daratumumab + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04151667",
            "title": "Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6346,
                    "therapyName": "Daratumumab + Dexamethasone",
                    "synonyms": null
                },
                {
                    "id": 5100,
                    "therapyName": "Bortezomib + Daratumumab + Dexamethasone",
                    "synonyms": null
                },
                {
                    "id": 4853,
                    "therapyName": "Daratumumab + Dexamethasone + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04162210",
            "title": "Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)",
            "phase": "Phase III",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 3792,
                    "therapyName": "Dexamethasone + Pomalidomide",
                    "synonyms": null
                },
                {
                    "id": 7747,
                    "therapyName": "GSK2857916",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04176380",
            "title": "RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9131,
                    "therapyName": "RAPA-201 T cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04178902",
            "title": "A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9130,
                    "therapyName": "ABBV-467",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04181827",
            "title": "A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4)",
            "phase": "Phase III",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 7751,
                    "therapyName": "Daratumumab + Dexamethasone + Pomalidomide",
                    "synonyms": null
                },
                {
                    "id": 4501,
                    "therapyName": "Bortezomib + Dexamethasone + Pomalidomide",
                    "synonyms": null
                },
                {
                    "id": 9007,
                    "therapyName": "Bortezomib + Cyclophosphamide + Dexamethasone + Fludarabine + JNJ-68284528 + Pomalidomide",
                    "synonyms": null
                },
                {
                    "id": 9008,
                    "therapyName": "Cyclophosphamide + Daratumumab + Dexamethasone + Fludarabine + JNJ-68284528 + Pomalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04196491",
            "title": "A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4) (KarMMa-4)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1164,
                    "therapyName": "Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 9413,
                    "therapyName": "bb2121 + Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04205409",
            "title": "Nivolumab for the Treatment of Relapsed or Refractory Hematologic Malignancies",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04214093",
            "title": "A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9118,
                    "therapyName": "AZD0466",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04268199",
            "title": "A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment (EASE)",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04268498",
            "title": "A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7757,
                    "therapyName": "Carfilzomib + Dexamethasone + Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 3342,
                    "therapyName": "Bortezomib + Dexamethasone + Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 9356,
                    "therapyName": "Carfilzomib + Daratumumab + Dexamethasone + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04280328",
            "title": "Study of CPI-444 as a Single Agent and in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9398,
                    "therapyName": "CPI-444 + Daratumumab",
                    "synonyms": null
                },
                {
                    "id": 3571,
                    "therapyName": "CPI-444",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04283097",
            "title": "Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9479,
                    "therapyName": "KPG-818",
                    "synonyms": null
                }
            ]
        }
    ]
}